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Macrophages are key players in the innate immune system and contribute significantly to 
inflammation in ischemic tissues, such as the infarcted heart. During inflammation, 
macrophages are involved in tissue remodeling, which is needed for the reconstitution of the 
inflamed organ. Ischemic and inflamed tissues are characterized by a scarcity of oxygen. 
Macrophages migrate to the site of inflammation against the O2-gradient and therefore have to 
adapt rapidly to low oxygen concentrations. This adaptation is mediated by the hypoxia 
inducible factor (HIF)/prolyl-4-hydroxylase domain enzyme (PHD) pathway. The HIF-α 
subunit is hydroxylated by the three PHDs (PHD1-3) in an oxygen-dependent way. In 
normoxia, PHD2 has been described to be the main oxygen sensor. In hypoxia, HIF is 
stabilized and induces a specific gene expression programme. This ensures the survival of the 
cell in conditions of low oxygen availability.  
I analyzed the impact of PHD2 on macrophage function using myeloid specific conditional 




) and a stably transduced RAW264.7 (RAW) 
macrophage cell line that express a PHD2 shRNA construct resulting in a knockdown of 
PHD2. In PHD2 deficient RAW cells and bone marrow derived macrophages (BMDMs), a 
normoxic stabilization of HIF-1α was observed. The expression of the HIF target genes such 
as pyruvate dehydrogenase kinase 1 (PDK1) was increased in PHD2 deficient macrophages 
compared to wt cells under normoxic conditions. PDK1 is an important mediator of the 
metabolic adaptation during hypoxia and stimulates the shift to anaerobic glycolysis. 
Increased expression of PDK1 resulted in metabolic reprogramming in PHD2 deficient 
macrophages which was shown by increased lactate levels and decreased ATP levels. 
Compared to wildtype macrophages, PHD2 deficient macrophages demonstrated decreased 
oxygen consumption rates and increased glycolysis. The observed glycolytic phenotype was 
associated with an impaired migration and phagocytosis. The glycolytic phenotype and the 
defect in migration and phagocytosis were partially reversed by pharmacological inhibition of 
PDK using dichloroacetate (DCA). In summary, my data suggest that PHD2 plays an 
important role in macrophage function by modulating cellular metabolism through PDK1.  





Oxygen availability is a prerequisite for proper metabolism and function of all complex 
multicellular organisms (reviewed in (Carreau et al., 2011)). Consequently, optimal oxygen 
delivery to tissues and cells is crucial. As diffusion is not sufficient to provide enough oxygen 
to meet the metabolic needs of complex multicellular organisms, several strategies have been 
evolved to augment oxygen uptake and transport to the tissue. In mammals, oxygen is 
absorbed by the lungs and transported via the cardiovascular system.  
To distinguish between different concentrations of oxygen in cell culture, the following terms 
are commonly used: Normoxia is defined as the oxygen partial pressure (pO2) as measured at 
sea level, thus 19.95 %, 150 mmHg or 20.3 kPa. Most cell culture experiments are performed 
at this condition. Within the body, the normal pO2 is much lower and can vary a lot between 
different tissues, e.g. ranging from a pO2 of 150 mmHg in the upper airways to 5 mmHg in the 
retina (reviewed in (Taylor, 2008)). The normal pO2 of a tissue is defined as tissue normoxia 
(reviewed in (Carreau et al., 2011). Hypoxia takes place when the pO2 is lower than the 
normoxic concentration and occurs when the oxygen demand exceeds the oxygen availability.  
Several adaptive mechanisms have developed to ensure adequate oxygen supply under 
hypoxic conditions (reviewed in (Taylor, 2008)). Examples of adaptive mechanisms are 
increase in the respiratory rate, in erythropoiesis and in angiogenesis. Furthermore, the 
metabolism can switch from aerobic to an anaerobic metabolism to use the remaining oxygen 
in the most efficient manner. 
Hypoxia can occur under physiological and non-physiological conditions. During exercise, 
the oxygen demand of the working muscle increases (reviewed in (Garvey et al., 2012)). If the 
cardiovascular system cannot transport enough oxygen to keep up with this demand, hypoxia 
occurs. Hypoxia also occurs at high altitude because of the reduction of atmospheric pO2 
(reviewed in (Wilkins et al., 2015). For example on top of the Mount Everest (approximately 
8400 m), the pressure of the inspired oxygen decreases from approximately 150 mmHg at sea 
level to 43 mmHg. Furthermore, hypoxia is essential for embryonic development as much of 
the mammalian embryogenesis occurs at low oxygen concentrations (Chen et al., 1999; 
Dunwoodie, 2009; Lee et al., 2001). Studies using the hypoxia marker pimonidazole showed 
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that hypoxia occurs within the embryo at different regions and at different times during organ 
development (Lee et al., 2001). These hypoxic regions were shown to be necessary for the 
development of fetal vascularization of the placenta (Dunwoodie, 2009). Pathophysiological 
conditions of hypoxia include progressive air flow limitation, e.g. chronic obstructive 
pulmonary disease (Kent et al., 2011). Furthermore it also occurs during ischemia, such as 
after myocardial infarction and often in tumors (reviewed in (Semenza, 2014; Vaupel and 
Mayer, 2007).  
Therefore, a tight regulation of the oxygen availability is necessary. The key regulators of the 
hypoxic response at the cellular level are hypoxia inducible factors (HIF) (reviewed in 
(Dengler et al., 2014) ).  
 
1.2. Macrophages 
Macrophages were originally identified by Ilya Metchnikoff more than 100 years ago, and his 
description of phagocytosis was awarded with the Nobel Prize for Medicine in 1908 
(reviewed in (Gordon, 2016)). 
Macrophages are essential innate immune cells and provide an important front line in the 
defense against pathogens (reviewed in (Sica and Mantovani, 2012)). Furthermore, they are 
also involved in homeostatic processes, such as tissue remodeling during embryogenesis and 
wound healing (Camp and Martin, 1996; Goren et al., 2009; Mirza et al., 2009). Macrophages 
are key players in the mediation of the inflammatory reaction and host defense and have an 
exceptional diversity and plasticity (reviewed in (Gordon and Martinez, 2010; Sica and 
Mantovani, 2012)). Peripheral-blood mononuclear cells (PBMC) are continuously released 
into the blood stream where they circulate for one to two days before entering the tissue to 
differentiate into macrophages (reviewed in (Mosser and Edwards, 2008). PBMCs are derived 
from myeloid progenitor cells in the bone marrow. These myeloid progenitor cells are also 
precursor cells for granulocytes and in part dendritic cells (reviewed in (Hume, 2015). The 
differentiation into macrophages or dendritic cells is dependent on the cytokine environment 
and on the activation of pattern recognition receptors (reviewed in (Geissmann et al., 2010)).  
Mononuclear phagocytes react to environmental stimuli, such as microbial products, cell 
debris and activated lymphocytes with distinct polarization (reviewed in (Hume, 2015; 
Mosser and Edwards, 2008; Sica and Mantovani, 2012). They contain receptors that enable 
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them to sense a broad range of signals and change their phenotype accordantly. Initially, 
macrophages polarization states were subdivided in M1 and M2 polarization of macrophages. 
In this subdivision, M1-polarized macrophages (or classically activated macrophages) are 
stimulated by Toll-like receptor ligands, interferon-γ (IFNγ) and tumour necrosis factor α 
(TNFα) (reviewed in (Biswas and Mantovani, 2012; Sica and Mantovani, 2012). Recognition 
of bacterial compounds, e.g. liposaccharide (LPS) can also result in M1 polarization of 
macrophages. M1 macrophages are described to be pro-inflammatory and tissue destructive. 
These macrophages are characterised by the expression of pro-inflammatory cytokines (such 
as interleukin-1β, interleukin-6 (IL-6), interleukin-12 (IL-12), interleukin-23 (IL-23) and 
TNFα), inducible nitric oxidase (iNOS), promotion of Th1 responses and have an important 
role in the clearance of pathogens. 
On the other hand, M2-polarized macrophages (or alternative activated macrophages) are 
induced by interleukin-4/interleukin-13 (IL-4/IL-13). These macrophages are characterised as 
anti-inflammatory and are described to be involved in tissue remodeling as well as in 
angiogenesis. Furthermore, macrophages of this phenotype are involved in the clearance of 
parasites. Additional cellular markers for this polarization state are arginase-1, found in 
inflammatory zone 1 (Fizz 1) and Ym1 (Raes et al., 2002). Stimulation with IL10 and 
immune complexes can also induce a M2-like phenotype which is immune-regulatory and 
involved in pro-tumoral functions (reviewed in (Biswas and Mantovani, 2012)). These 
subdivisions, however, do not reflect the heterogeneity of macrophage polarization. Today, 
macrophage polarization states are rather described as a broad spectrum ranging from M1 to 
M2 with every intermediate state being independently defined depending on the nature of the 
polarization stimulus (reviewed in (Hume, 2015; Mosser and Edwards, 2008). 
1.2.1. Macrophages and hypoxia 
Ischemic and inflamed tissues are characterised by a scarcity of oxygen. The ability of the 
affected tissue to survive the reduction in oxygen and energy supply as well as the growth of 
new blood vessels is important for the outcome of an ischemic disease (Semenza, 2010). 
Migration into and accumulation of macrophages inside the damaged tissues is critical for 
these tissue remodeling processes. Azzawi et al. showed that macrophages accumulate in the 
cardiac tissue after myocardial infarction with macrophage accumulation peaking at day 5-7 
(Azzawi et al., 2005). Cell migration is significantly affected by tissue oxygenation, which is 
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severely impaired in ischemia. Approximately 95% of the myeloid cells migrate to the 
inflamed region rather than being resident at this tissue (reviewed in (Cramer et al., 2003; 
Lewis et al., 1999)). Therefore, myeloid cells need to be recruited to the site of inflammation 
against the oxygen gradient.  
In hypoxic conditions, macrophages undergo a metabolic reprogramming to cope with the low 
oxygen availability and to be able to meet their energy requirements (reviewed in (Riboldi et 
al., 2013)). This is achieved by the induction of several genes by HIF. Hypoxic conditions 
have been reported to affect myeloid cell function in vitro regarding phagocytic capacity, cell 
surface marker expression, adhesion, migration and cell survival (reviewed in (Cramer et al., 
2003; Riboldi et al., 2013)). It has been shown that macrophages accumulate in hypoxic 
regions, such as the ischemic myocardium, stabilize HIF and induce HIF-mediated gene 
expression (Burke et al., 2003; Jurgensen et al., 2004). 
 
1.3. The Hypoxia-Inducible Factor (HIF) 
In hypoxic conditions, myeloid cells and other cell types adapt to the environmental challenge 
via the induction of a specific gene expression program which is mediated by the hypoxia 
inducible factors (HIF). To date, HIFs are described to exist in all metazoan species (Loenarz 
et al., 2011). HIF-regulated gene expression controls the transcription of many genes involved 
in the systemic and cellular response to hypoxia (reviewed in (Liu et al., 2012; Semenza, 
2004)). This leads to the promotion of angiogenesis and erythropoiesis as well as to the 
expression of genes involved in the metabolic adaption to hypoxic conditions (Bruick, 2000; 
Fukuda et al., 2007; Papandreou et al., 2006; Zhang et al., 2008).  
1.3.1. Structure of HIF 
HIF transcription factors are heterodimers consisting of one of the α-subunits HIF-1α, HIF-2α 
or HIF-3α and a β-subunit (also called aryl hydrocarbon receptor nuclear translocator 
(ARNT)) (reviewed in (Dengler et al., 2014)). The two subunits are members of the Per-Arnt-
Sim (PAS) family containing a basic helix-loop-helix domain (bHLH) (Wang et al., 1995). 
The heterodimer binds to a specific DNA motif, the Hypoxia Responsive Elements (HREs). 
This binding then induces transcriptional activation of the target gene (reviewed in (Dengler 
et al., 2014)). The HIF-1α subunit contains two transactivation domains (TAD) that are 
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located at the N-terminus (N-TAD, aa 531-575) and at the C-terminus (C-TAD, aa 786-826) 
(Fig.1). The C-TAD can be bound by co-activators like CBP/p300 to activate transcription 
(Jiang et al., 1997; Kallio et al., 1998; Pugh et al., 1997). Furthermore, the HIF-α subunit 
contains an oxygen-dependent degradation domain (ODD) (Pugh et al., 1997). The ODD 
contains two conserved proline residues (P402/P564). These proline residues can be 
hydroxylated by the prolyl-4-hydroxylase domain enzymes (PHDs) (Ivan et al., 2002; 
Jaakkola et al., 2001). Additionally, the asparagine residue 803 (Asn803) in the C-TAD can 
be hydroxylated by factor inhibiting HIF (FIH) (Lando et al., 2002; Mahon et al., 2001). 
 
Figure 1: Domain structure of HIF-1α. The bHLH and the PAS domain are needed for DNA binding and dimerization, 
respectively. There are two transactivation domains present in the HIF-1α protein: The N-TAD which resides in the oxygen-
dependent degradation domain (ODD) and the C-TAD located at the C-terminal end. The ODD can be hydroxylated at two 
proline residues (P402, P564) by hydroxylating enzymes which leads to the oxygen-dependent degradation of HIF-1α. The 
C-TAD contains an asparagine residue (N803), which can be hydroxylated by FIH-1 leading to altered transcriptional 
activity. 
The first discovered isoform was HIF-1α. It was found by analyzing proteins that bind to the 
HRE of the erythropoietin gene (EPO) (Semenza and Wang, 1992). The other two α-subunits 
were identified using gene homology searches and by analyzing protein interaction partners of 
HIF-1β (reviewed in (Dengler et al., 2014)). HIF-1α and HIF-2α have a high similarity in 
bHLH and PAS domains and both bind to HREs to induce the transcription. HIF-1α
-/- 
mice die 
at embryonic day (E) 9.5 due to severe defects in vascularization, impaired neural folding and 
due to the reduction of somites (Iyer et al., 1998; Ryan et al., 1998). HIF-2
-/-
 mice also die in 
the embryo stage (Peng et al., 2000; Tian et al., 1998). Depending on the mouse model used 
this was due to brachycardia or vascular disorganization. HIF-1α and HIF-2α are known to 
have different roles in the adaption of cells to hypoxic conditions: HIF-1 initiates the response 
to hypoxia, whereas HIF-2 is important for the adaptation to long-term hypoxia (Koh et al., 
2011). The HIF-3α subunit is less similar compared to HIF-1α and HIF-2α. There are at least 
six splice variants of HIF-3α which have variable oxygen sensitivity and differences in their 
regulatory functions of transcription (reviewed in (Dengler et al., 2014). When expressed as 
an alternative splice variant called HIF3-α4 which is highly similar to the murine Inhibitory 
PAS domain protein 1, it negatively regulates the HIF-1α response (Dengler et al., 2014; 
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Makino et al., 2007; Maynard et al., 2005). This variant lacks the TAD and therefore does not 
activate target gene expression, but rather acts as a HIF-1α inhibitor. 
1.3.2. Regulation of HIFs by Prolyl-4-Hydroxylase Domain enzymes (PHD) and the 
Factor Inhibiting HIF (FIH) 
The HIF-1β subunit is stably expressed and its mRNA and protein levels are not affected by 
changes in oxygen availability. On the contrary, the regulation of HIF-α occurs at the level of 
protein stability through the action of hydroxylating enzymes (Fig.2). HIF-1α is hydroxylated 
in the ODD domain by the prolyl-4 hydroxylase domain enzymes (PHDs) (Bruick and 
McKnight, 2001; Epstein et al., 2001). The hydroxylation by the PHDs targets HIF-1α for 
proteasomal degradation which is mediated by the pVHL-E3-ubiquitin-ligase complex 
(Huang et al., 1998; Maxwell et al., 1999; Ohh et al., 2000; Pause et al., 1999; Tanimoto et 
al., 2000). These processes result in a half-life time of the HIF-α subunit of approximately 
five minutes in normoxic conditions (Moroz et al., 2009). The Km-values of the PHDs for 
oxygen are between 230-250 µM which is only slightly above the values for the atmospheric 
pO2 at sea level and therefore also above the oxygen concentrations observed in physiological 
conditions in many tissues (Hirsila et al., 2003). This causes the PHDs to have a relatively 
low affinity to oxygen. This feature makes them suitable oxygen sensors in mammals. At low 
oxygen concentrations the hydroxylation of the HIF-α subunits ceases and HIF-α is stabilized.  
Stabilization of the HIF-1α subunit is not sufficient to induce HIF target gene expression 
(reviewed in (Ke and Costa, 2006)). The transcriptional activity of HIF-1 is inhibited by the 
interaction with the factor inhibiting HIF-1 (FIH-1) (Hewitson et al., 2002; Lando et al., 2002; 
Mahon et al., 2001). FIH-1 hydroxylates a conserved asparagine residue (Asn803) in the C-
TAD of the HIF-1α subunit in an oxygen sensitive manner. Hydroxylation of this residue 
blocks the interaction of HIF-1α with the transcription adaptors cAMP response element-
binding protein (CREB)-binding protein (CBP) and p300 ((Arany et al., 1996) and reviewed 
in (Dengler et al., 2014)). Inhibition of CBP/p300 recruitment by FIH-1 thereby inhibits the 
execution of HIF-1 transcriptional activity. 
 
 





Figure 2: Summary of the regulation of HIF-1α protein levels. In normoxia, hypoxia-inducible factor 1-α (HIF-1α) is 
located in the cytosol and hydroxylated by prolyl-4 hydroxylase domain enzymes (PHDs). This hydroxylation leads to the 
ubiquitination of HIF-1α by von Hippel-Lindau tumor suppressor protein (pVHL) and subsequently to the proteasomal 
degradation of the HIF-1α subunit. HIF-1α is also hydroxylated by factor inhibiting HIF (FIH) thereby blocking the 
interaction of HIF-1α with cAMP response element-binding protein (CREB) and p300 (CBP/p300). In hypoxia, the 
hydroxylation of HIF-1α ceases and HIF-1α translocates to the nucleus and dimerizes with hypoxia-inducible factor 1-β 
(HIF-1β). After binding to CBP/300, the transcription of HIF target genes, such as vascular endothelial growth factor 
(VEGF), erythropoietin (EPO), Glucose transporter 1 (GLUT1) and pyruvate dehydrogenase kinase 1 (PDK1) is induced.  
1.3.3. HIF target genes 
HIFs are the principal transcriptional regulators of oxygen-dependent gene expression with at 
least 100 known target genes (reviewed in (Liu et al., 2012)). The target genes are involved in 
the regulation of angiogenesis, cell migration and metabolic adaptation to scarce oxygen 
availability. Induction of these processes leads to a decrease in oxygen consumption of the 
cells and to an increase of oxygen delivery to the cells in order to maintain an adequate 
oxygen supply to the tissue (Fukuda et al., 2007; Papandreou et al., 2006). The oxygen 
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transport is mediated by HIF-1 via the expression of EPO (reviewed in (Li et al., 2004).). EPO 
stimulates erythroid progenitor cells to increase erythropoiesis. Furthermore, it is also 
involved in the proliferation and differentiation of other cell types such as endothelial cells, 
vascular smooth muscle cells, neurons and neuronal progenitor cells. HIF-1 also induces the 
expression of inducible nitric oxide synthase (iNOS) (Melillo et al., 1995). This increases 
vasodilatation and hence facilitates oxygen delivery. A very prominent HIF-target gene is the 
vascular endothelial growth factor (VEGF) which stimulates angiogenesis and vascularization 
(Forsythe et al., 1996; Liu et al., 1995). All these adaptions increase the oxygen transport to 
the tissue and thereby improving the oxygen availability in the tissue.  
1.3.4. Metabolic adaptations to hypoxia 
In order to meet energy demands in hypoxic conditions, the cellular energy metabolism needs 
to be adapted to the decrease in oxygen availability. Therefore, the metabolism is shifted from 
aerobic to anaerobic glycolysis. In normoxia, glucose enters the cell and is metabolized in 
several steps to pyruvate which enters the mitochondria and is there converted to acetyl-CoA 
by pyruvate dehydrogenase (PDH) (reviewed in (Dashty, 2013; Taylor, 2008)) (Fig.3). Acetyl 
CoA is used in the tricarboxylic acid (TCA) cycle to produce ATP and to reduce NAD+ to 
NADH. NADH, in turn is then fed into the respiratory chain. The respiratory chain consists of 
four enzymes: NADH hydrogenase (complex I), succinate-ubiquinone oxidoreductase 
(complex II), ubiquinol cytochrome c oxidoreductase (complex III), cytochrome c oxidase 
(COX, complex IV). The first four enzymes (complex I-IV) and the two mobile electron 
carriers ubiquinone and cytochrome c form the respiratory chain. The respiratory chain 
couples electron transport with pumping of protons to build up the electrochemical gradient 
needed by the ATP synthase to produce ATP.  
HIF-1 mediates the shift towards anaerobic glycolysis by the upregulation of several target 
genes, such as the Glucose transporter 1 (GLUT1) (Ebert et al., 1995; Hayashi et al., 2004) to 
increase glucose uptake and the expression of enzymes which are involved in the glycolytic 
pathway such as the phosphofructokinase 1 (PFK1) and lactate dehydrogenase (Firth et al., 
1995; Obach et al., 2004; Semenza et al., 1996; Semenza et al., 1994). Furthermore, HIF-1 
represses oxygen consumption and attenuates mitochondrial respiration by the induction of 
PDK1 (Kim et al., 2006; Papandreou et al., 2006). Phosphorylation by PDK1 inhibits the 
action of PDH. It was first shown by Linn et. al. that mitochondrial function could be 
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regulated by phosphorylation of PDH and that this is mediated by PDKs (Linn et al., 1969). 
PDH is one part of a mitochondrial multi-enzyme complex that catalyzes the oxidative 
decarboxylation of pyruvate to acetyl-CoA (reviewed in (Sugden and Holness, 2003)). This 
reduces the flux of acetyl CoA through the mitochondrial TCA cycle and the electron 
transport chain and reduces the mitochondrial oxygen consumption likewise.  
Another mechanism which increases respiratory efficiency in hypoxic cells is the regulation 
of cytochrome c oxidase (COX) activity (Fukuda et al., 2007). During hypoxia, HIF-1α 
induces the transcription of the genes encoding the COX4-2 subunit and the Lon protease. 
This mitochondrial protease degrades the subunit COX4-1 which is predominantly expressed 
in normoxic conditions. The cytochrome c subunit switch (COX4-1 to COX4-2) increases the 
efficiency of complex IV of the mitochondrial electron transport chain regarding quantity of 
ATP and reactive oxygen species (ROS) produced. By doing so, mitochondrial oxygen 
consumption is reduced. If the metabolic adaptation fails, HIF-1 induces the expression of 
BCL/adenovirus E1B 19 kDa interacting protein 3 (BNIP3) to prevent increased ROS levels 
and cell death in hypoxic cells (Bruick, 2000; Zhang et al., 2008). BNIP3 competes for 
binding to Bcl-2, releasing Beclin-1 to stimulate mitochondrial autophagy (Maiuri et al., 
2007). 
Altogether, these changes reduce the flux through the mitochondrial TCA cycle and the 
electron transport chain. This decreases oxygen consumption and reduces the accumulation of 
ROS likewise. 




Figure 3: Induction of metabolic adaptation by hypoxia-inducible factor (HIF). In normoxia, glucose is 
converted to pyruvate which enters the mitochondria and is there metabolized to acetyl-CoA by pyruvate 
dehydrogenase (PDH). Acetyl CoA then enters the tricarboxylic acid cycle (TCA). In hypoxia, HIF-1 
transcriptionally upregulates the expression of glucose transporter 1 (Glut1) and phosphofructokinase 1 (PFK1). 
HIF inhibits pyruvate dehydrogenase (PDH) by transcriptionally increasing the expression of PDH kinase 
(PDK), which phosphorylates and inactivates PDH. HIF-1 also leads to changes in the respiratory chain. In 
normoxia, Cox 4-1 is the predominant isoform of Cox4. During hypoxia, HIF-1α activates Lon Protease to 
degrade Cox 4-1 and also upregulates Cox 4-2 to replace Cox 4-1. 
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1.4. Prolyl-4-hydroxylase domain enzymes (PHDs)  
PHDs are evolutionarily conserved oxygen sensors in metazoans. The PHDs belong to the 
iron- and α-ketoglutarate-dependent dioxygenase superfamily and were discovered after 
confirming that oxygen-sensitive enzymes modify the ODD of the HIF-1α subunit (Huang et 
al., 1998; Jaakkola et al., 2001).  
Worms and flies have only one PHD whereas there exist at least three members of the PHD 
protein family in mammals: PHD1 (also EGLN2), PHD2 (also called EGLN1) and PHD3 
(also called EGLN3) (Bruick and McKnight, 2001; Epstein et al., 2001; Kaelin and Ratcliffe, 
2008). Recently, a fourth member of the PHD family, the prolyl 4-hydroxylase 
transmembrane (TM-HIF-P4H), was identified, but its function is not fully characterised yet 
(Koivunen et al., 2007; Laitala et al., 2012). In general, all three PHD isoforms are 
ubiquitously expressed, but expression levels vary between the tissues (Appelhoff et al., 2004; 
Cioffi et al., 2003; Lieb et al., 2002).  PHD2 is constitutively expressed in all tissues, whereas 
PHD1 is highly expressed in the testis and hormone responsive tissues and PHD3 is 
predominantly expressed in heart, skeletal muscles and in the placenta. Studies using PHD 
proteins fused to the Green Fluorescent Protein (GFP) showed that PHD1 is mainly localized 
in the nucleus, PHD2 is predominantly localized in the cytoplasm and PHD3 is distributed 
homogenously in both compartments (Metzen et al., 2003; Metzen et al., 2005) 
1.4.1. Role of PHDs 
Oxygen-dependent degradation after PHD-mediated hydroxylation is the primary pathway of 
regulating the activity of HIF transcription factors (Epstein et al., 2001). In normoxic 
conditions, the two critical prolines of the ODD (Pro564 and Pro402) are hydroxylated by 
PHDs in the presence of oxygen targeting HIFα for proteasomal degradation. Mutation in 
either proline is sufficient for HIFα-stabilization in normoxic conditions. Studies reported that 
the two proline residues of HIFα are differently regulated by the PHDs (Chan et al., 2005; 
Epstein et al., 2001; Huang et al., 2002). Using hydroxylation specific antibodies, it was 
shown that in normoxic conditions Pro564 is hydroxylated prior to Pro402 and that a mutation 
in Pro564 also reduces the hydroxylation of Pro402. Furthermore, Pro402 showed an oxygen-
dependent decrease in hydroxylation at high oxygen tensions indicating that hydroxylation of 
Pro402 is highly responsive to changes in oxygen and therefore has a more important role in 
HIF regulation in hypoxic conditions (Chan et al., 2005). In addition to that, it was reported 
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that PHD2 has higher affinity for Pro402 than for Pro564 (Huang et al., 2002). PHD2 and 3 
have a similar catalytic activity towards a synthetic hydroxylated HIF-1α peptide, whilst the 
catalytic activity of PHD1 is lower (Tuckerman et al., 2004). Studies using RNA-interference 
revealed that silencing of PHD2 is sufficient to stabilize and activate HIF-1α in normoxia, 
whilst silencing of either PHD1 or PHD3 alone has no effect on HIF-1α stability in normoxia 
(Berra et al., 2003). This suggests that PHD2 is the critical oxygen sensor in normoxia. PHD2 
and PHD3 show an upregulation in hypoxia whereas PHD1 is expressed constitutively 
(Epstein et al., 2001; Metzen et al., 2003). This suggests a negative feedback loop in the 
regulation of the HIF-mediated response (Appelhoff et al., 2004; del Peso et al., 2003; 
Pescador et al., 2005). 
1.4.2. PHD hydroxylation reaction  
PHD enzymes catalyze a hydroxylation reaction (reviewed in (Berra et al., 2006; McDonough 
et al., 2006)). For this, a single non-heme bound Fe
2+
 is needed for the activation of O2 and as 
a template for the correct binding of the reactants. One oxygen atom is added to peptidyl 
proline resulting in the formation of hydroxyproline. The remaining oxygen atom is used in a 
coupled decarboxylation reaction that results in α-ketoglutarate to be converted to succinate. 
In this reaction also CO2 and Fe
3+ 
are produced. The hydroxylation reaction is furthermore 





can then be used in the next catalytic cycle (Counts et al., 1978; Nietfeld and Kemp, 1981; 
Schofield and Ratcliffe, 2004; Smirnova et al., 2012). Depletion of ascorbate was found to 
inhibit PHD function and to stabilize HIF-1α in human cancer cells (Knowles et al., 2003).  
 
Figure 4: Hydroxylation reaction of prolyl-4-hydroxylases (PHD). The PHDs utilize O2 and α-ketoglutarate as substrates 
and Fe2+ as co-factor. In the hydroxylation reaction, 4-hydroxyproline and succinate are formed. 
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1.4.3. Biological function of PHDs 
Several genetically modified mouse models have been developed to study the role of PHDs in 
vivo.  
1.4.3.1. PHD1 genetically modified mouse models 
PHD1 is reported to have a role in mitochondrial metabolism (Aragones et al., 2008) and 
ROS production (Schneider et al., 2010). PHD1
-/- 
mice showed no obvious phenotype under 
non-stressed conditions except for a reduced mitochondrial oxygen consumption rate (OCR) 
in skeletal muscle cells (Aragones et al., 2008). This metabolic reprogramming decreased 
muscle performance in healthy tissue. On the other hand, knockout of PHD1 was shown to 
attenuate myocardial ischemia/reperfusion injury in the isolated heart by enhancing HIF-1α 
signaling (Adluri et al., 2011). Furthermore, PHD1
-/- 
mice were protected against colitis 
(Tambuwala et al., 2010). This was associated with an improved epithelial barrier function 
because of decreased epithelial apoptosis. Reduced apoptosis upon PHD1-depletion was also 
described in a model of hyperoxia-induced vascular obliteration in the retina (Huang et al., 
2011). Liver regeneration was significantly improved in PHD1
-/-
 mice due to an enhanced 
proliferation of hepatocytes indicating a role of PHD1 on cell cycle progression (Mollenhauer 
et al., 2012). Until now, no myeloid specific PHD1 knockout mouse model has been 
generated and the role of PHD1 in macrophage function has not been described.  
1.4.3.2. PHD3 genetically modified mouse models 
Mice with a general knockout of PHD3 showed a reduction of neuronal apoptosis, reduced 
function of the sympathoadrenal system and systemic hypotension (Bishop et al., 2008). 
Additionally, depletion of PHD3 was described to be protective against cardiomyocyte 
apoptosis after ischemia/reperfusion injury (Xie et al., 2015). Furthermore, PHD3 was 
described to have a function in the hypoxic regulation of the innate immune response 
(Thompson et al., 2013). PHD3
-/-
 neutrophils showed a decreased hypoxic survival compared 
with wild type (wt) cells (Walmsley et al., 2011). Analysis of PHD3
-/-
 bone marrow derived 
macrophages (BMDM) showed a role of PHD3 in the regulation of macrophage function. One 
study showed a role of PHD3 in macrophage differentiation five days after differentiation 
which was accompanied with a change to a pro-inflammatory phenotype of the macrophages 
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(Kiss et al., 2012). Another study could also observe an effect of PHD deficiency in the 
differentiation of BMDMs until day 5 (Swain et al., 2013). Anyhow, eight days after the onset 
of the differentiation, no differentiation difference was observed and also M1 and M2 
polarization was unchanged between PHD3
-/-
 and wt BMDMs. Under stress conditions, 
PHD3-deficient BMDMs displayed a reduction in TUNEL positive cells and had decreased 
apoptosis.  
1.4.3.3. PHD2 genetically modified mouse models 
Previous studies showed that PHD2
-/-
 mouse embryos die between day E 12.5 and E14.5 due 
to severe vascular defects in placenta and heart during embryogenesis (Minamishima et al., 
2008; Takeda et al., 2006). PHD2 is essential for HIF-1α-mediated angiogenesis since 
postnatal somatic deletion of PHD2 in mice resulted in increased density and size of blood 
vessels, whereas loss of PHD1 or PHD3 did not have comparable effect (Takeda et al., 2007). 
Additionally, somatic PHD2 inactivation was found to lead to profound polycythemia 
(Minamishima et al., 2008). 
Work performed in various inducible mouse models indicate that the effect of PHD2 depends 
very much on the targeted cell type. Depending on the cell type in which PHD2 has been 
manipulated, i.e. tumor cells or endothelial cells, PHD2 was found to be a potent mediator of 
tumor angiogenesis pathways or in vessel normalization in tumors (Chan et al., 2009; 
Mazzone et al., 2009). Haplodeficiency of PHD2 had no effect on the density of tumor vessels 
and lumen size, but changed the phenotype of endothelial tip cells to a more quiescent cell 
type. Additionally, it enhanced vessel maturation leading to an improved tumor perfusion and 
less tumor cell invasion (Mazzone et al., 2009). On the other hand, interleukin 8 (IL-8) and 
angiogenin are produced by PHD2 deficient tumor cells and contribute to bone marrow-
derived cell mobilization and angiogenesis which increases tumor growth. These two factors 
were found to be mediated by PHD2 in tumor cells in a HIF-independent manner providing 
evidence for a critical role of PHD2 per se in controlling tumor growth (Chan et al., 2009). 
Furthermore, conditional ablation of PHD2 in myeloid cells and T-lymphocytes reduced 
tumor volume (Mamlouk et al., 2014). This effect was mediated by the overall 
downregulation of both anti-inflammatory cytokines and pro-inflammatory cytokines. In 
addition, Kalucka et al. found that only PHD2-deficiency in keratinocytes, but not in myeloid 
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cells led to a faster wound closure induced by an enhanced migratory capacity (Kalucka et al., 
2013). 
Invading macrophages are major players for tissue regeneration and angiogenesis in ischemic 
tissues. PHD2
+/-
-heterozygous mice had more M2-like polarized macrophages which are 
important for the preservation of tissue perfusion and protection (Takeda et al.). Accordantly, 
PHD2
+/- 
mice exhibited increased viability of the ischemic tissue in a model of hindlimb 
ischaemia. Furthermore PHD2
+/-
 mice were also protected from myocardial ischemia. 
Desmin-stainings showed less cardiomyocyte death in PHD2
+/- 
 mice compared to wt controls 
24 h after coronary artery ligation. Most interestingly, these findings were obtained with 
PHD2
+/-
 mice and LysMCrexPHD2
fl/+ 
mice and could not be recapitulated in LysM Cre PHD2 
fl/fl
 mice indicating a dose dependent effect (Ikeda et al., 2013; Takeda et al., 2011). In other 




 mice were found to 
have decreased markers of M1-polarization without a clear polarization to M2 macrophages 
which is in contrast to the observations above (Ikeda et al., 2013). PHD2 deficient 
macrophages displayed a decreased migratory capacity toward monocyte chemoattractant 
protein-1 (MCP-1) in a transwell migration assay. In a model of hypertension induced by L-
NAME and angiotensin-treatment, PHD2-deletion in macrophages led to less macrophage 
infiltration in the aorta, attenuated cardiovascular remodeling and preserved heart function. 
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1.5. Aims of this thesis 
Macrophages are key players of the innate immune system and are responsible for the rapid 
recognition of invading pathogens. They play an important role in the mediation of the 
inflammatory reaction and display a notable plasticity. Ischemic and inflamed tissues are 
characterised by scarce oxygen availability. Macrophages accumulate inside these tissues and 
are involved in remodelling processes. Therefore, they have to migrate against the oxygen 
gradient. Like other cells, macrophages adapt to the resulting hypoxic conditions via inducing 
a HIF-mediated gene expression program. The oxygen dependent hydroxylation of the HIF-α 
subunit by the PHDs marks HIF-α for proteasomal degradation. Of the three PHDs, PHD2 has 
been described to be the main oxygen sensor in normoxia. Deficiency of PHD2 has been 
reported to have cell type-specific effects. However, the effect of PHD2 in macrophages is not 
fully understood. To analyze the impact of PHD2 on macrophage function in further depth, I 





cKO) and stably transduced RAW cells expressing a PHD2 shRNA construct (shPHD2 
RAW). I aimed to investigate how metabolism and function of macrophages are influenced by 
PHD2 deficiency. To this end, the following objectives were defined: 
1. To analyse HIF-1α stabilization in PHD2 cKO and shPHD2 RAW macrophages in 
normoxia. 
2. To test if HIF-1 target genes are differentially expressed in PHD2 cKO and shPHD2 
RAW macrophages. 
3. To identify changes in macrophage function in PHD2 cKO and shPHD2 RAW 
macrophages. 
4. To characterize metabolic alterations in PHD2 cKO and shPHD2 RAW macrophages. 
5. To determine if the metabolic changes depend on the expression of the HIF target 
gene PDK1. 
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2. Material and Methods 
2.1. Cell lines 
 The cell lines used in this project are depicted in Table 1. 
 
Table 1: Cell lines 
Cell line Source Distributor Reference 
RAW264.7 Abelson murine leukemia virus 
transformed, macrophage  
Kindly provided by 
Dr. B. Wielockx,  
Institute of Pathology, 
TU Dresden GER 
(Raschke et 
al., 1978) 
MDA-MB 231 Human, Mammary 
Gland/Breast; epithelial 
kindly provided by 






L929 Murine, subcutaneous connective 
tissue, fibroblast 
ATCC, Wesel GER 
# CCL-1 
(Earle et al., 
1950) 
 
2.2.  Consumable supplies 
The consumable supplies are listed in Table 2. 
 
Table 2: Consumable supplies 
Consumables Manufacturer 
Cell culture flasks Greiner Bio-One, Kremsmünster AU 
Falcon tubes 15 ml Greiner Bio-One, Kremsmünster AU 
Falcon tubes 50 ml Greiner Bio-One, Kremsmünster AU 
Filter (0.22 µm) Roth, Karlsruhe GER 
Hybond
TM
C nitrocellulose membrane Amersham Biosciences, UK 
Original-Perfusor Syringe OPS 10 ml Braun, Melsungen GER 
Pasteur pipettes Sarstedt, Nümbrecht GER 
PCR-plate (96 well) Greiner Bio-One, Kremsmünster AU 
Pipette tips (w/o filters) Sarstedt, Nümbrecht GER 
Reaction tubes 0.5 ml Sarstedt, Nümbrecht GER 
Reaction tubes 1.5 ml Sarstedt, Nümbrecht GER 
Reaction tubes 2.0 ml Sarstedt, Nümbrecht GER 
Serological pipettes 10 ml Sarstedt, Nümbrecht GER 
Serological pipettes 25 ml Sarstedt, Nümbrecht GER 
Serological pipettes 5 ml Sarstedt, Nümbrecht GER 
Tissue culture dish 10 cm Greiner Bio-One, Kremsmünster AU 
Tissue culture dish 20 cm Greiner Bio-One, Kremsmünster AU 
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Tissue culture plates, 24 well Greiner Bio-One, Kremsmünster AU, Sarstedt, 
Nümbrecht GER 
Tissue culture plates, 6 well Greiner Bio-One, Kremsmünster AU 
Tissue culture plates, 96 well Sarstedt, Nümbrecht GER 
Luminometer plates (cell culture) Greiner Bio-One, Kremsmünster AU 
XF calibration plates Seahorse Bioscience, North Billerica, USA 
XF cell plates Seahorse Bioscience, North Billerica, USA 
X-ray films GE Healthcare, Munich, GER 
 
2.3.  Equipment 
The equipment used in this project is given in Table 3. 
 
Table 3: Equipment 
Application Instrument Manufacturer 
Centrifugation Centrifuge 5415R Eppendorf, Hamburg, GER 
Centrifuge 5810R Eppendorf, Hamburg, GER 
Micro Centrifuge Carl Roth, Karlsruhe, GER 
Cell freezer Nalgene freeze -80°C Nalgene, Rochester, USA 
Cleanbench Hera Safe KS 12 Thermo Electron, 
Langenselbold, GER 
Flow cytometer BD FACS Canto II 
Flowcytometer 
BD Biosciences, GER 
Fluorescence microscope Axio Observer D1 Zeiss, Oberkochen, GER 
Inverse light microscope Motic® AE30 TED, Pella Inc, USA 
Heating block Block thermos stat 
BT2000 
Kleinfeld Labortechnik, GER 
SDS-Page PerfectBlue Double gel 
system 
Peqlab, Erlangen, GER 
Shaker Minitron INFORNS HAT AG, 
Bottmingen, CH 
Cell culture incubator CB159 Binder, Tuttlingen, GER 
Luminometer Centro LB 960 Berthold, Bad Wildbad, GER 
Magnetic stirrer Ikamag®RH IKA Labortech, Staufen, GER 
Microplate Reader Model 680 Bio-Rad, München, GER 
Oxygen-controlled work 
station 
In Vivo2 400 Baker Ruskin Technologies, 
Bridgeend, UK 




XF96 analyzer Seahorse Bioscience, North 
Billerica, USA 
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PCR cycler Primus 96 Thermocycler Peqlab, Erlangen, GER 
Real-Time PCR cycler Mx3000P Strategene, La Jolla, USA 
UV-transilluminator InGenius Syngene, Cambridge, UK 
Vortex Vortex Genie 2 Scientific Industries, München, 
GER 
Water bath Störktronic W22 Medigen, Martinsried, GER 
Western blot transfer PerfectBlue Semi-Dry 
electroblotter 
Peqlab, Erlangen, GER 
HPLC system Shimadzu Shimadzu, Kyoto, JP 
 
2.4. Software 
The software used in this project is given in Table 4. 
Table 4: Software 
Program Application Source 
CorelDraw Image editor Corel Corporation, Ottawa, USA 
Image J Image analysis Imagej.nih.gov 




BLAST Sequence alignment Ncbi.nlm.nih.gov 
GraphPad Prism Statistical analysis GraphPad Software Inc, La Jolla, USA 
GraphPad Quickcalcs: 
outlier calculator 
Statistical analysis GraphPad Software Inc, La Jolla, USA 
Endnote References Thomson Reuters, Philadelphia, USA  
BD FACSDiva FACS analysis BD Biosciences, New Jersey, USA 
Flowing Software 2 FACS analysis Perttu Terhu, Turku Centre of 
Biotechnology, FI 
Windows Office Excel 
2010 
Data analysis Windows, Washington, USA 
 
  




The chemicals used in this project are given in Table 5. 
 
Table 5: Chemicals 
Chemical Order number Manufacturer 
Accutase P10-21100 PAA, Pasching, AUS 
Acrylamide 03029.1 Carl Roth, Karlsruhe, GER 
Adenosine-triphosphate (ATP) A2754 Sigma, St. Louis, USA 
Ascorbate A5960 Sigma, St. Louis, USA 
Albumine Bovine Fraction V (BSA) A1391 Applichem, Darmstadt, GER 
β-mercaptoethanol 4227.1 Carl Roth, Karlsruhe, GER 
Bradford solution 500-0006 Bio-Rad Laboratories GmbH, 
Munich, GER 
Bromphenol blue A512.1 Carl Roth, Karlsruhe, GER 
Chloroform 3313.1 Carl Roth, Karlsruhe, GER 
Complete Mini EDTA-free Protease 
Inhibitor 
04693124001 Roche, Mannheim, GER 
Complete Mini PhosStop 04906837001 Roche, Mannheim, GER 
Coumaric acid C-9008 Sigma, St. Louis, USA 
DC kit 500-0114 Bio-Rad Laboratories GmbH, 
Munich, GER 
DHE D2926 Sigma, St. Louis, USA 
DMSO 7029.1 Merck, Schwalbach/Ts, GER 
Dispase II P10-032100 PAN™ biotech, Passau, GER 
EDTA  8043.2 Carl Roth, Karlsruhe, GER 
ECL (Immobilon ™ Western 
Chemiluminescent HRP substrate) 
WBHL50500 Merck Millipore, Darmstadt, 
GER 
EGTA 3054.1 Carl Roth, Karlsruhe, GER 
Fetal calf serum P40-47500 PAN™ biotech, Passau, GER 
Glucose A3594 Carl Roth, Karlsruhe, GER 
Glycine 3908.2 Carl Roth, Karlsruhe, GER 
Glycerol 3783.2 Carl Roth, Karlsruhe, GER 
HEPES P05-01100 PAN™ biotech, Passau, GER 
H2DCFDA D399 Thermo Scientific, Waltham, 
USA 
Horse serum P30-0702 PAN™ biotech, Passau, GER 
Igepal  18896 Sigma, St. Louis, USA 
KCL 6781.1 Carl Roth, Karlsruhe, GER 
KH2PO4 6875.1 Carl Roth, Karlsruhe, GER 
KOH 6751.3 Carl Roth, Karlsruhe, GER 
L-Glutamine K0283 Biochrome, Berlin, GER 
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Luminol 4203.1 Carl Roth, Karlsruhe, GER 
Mannitol 4175.1 Carl Roth, Karlsruhe, GER 
Milk Powder 4021155023078 Sucofin, Zeven, GER 
Methanol 4627.5 Carl Roth, Karlsruhe, GER 
MgCl2 2189.2 Carl Roth, Karlsruhe, GER 
NaCl 9265.2 Carl Roth, Karlsruhe, GER 
NaOH 6771.2 Carl Roth, Karlsruhe, GER 
Natriumazide K305.1 Carl Roth, Karlsruhe, GER 
PageRuler™ Prestained Protein 
Ladder 
221616 Thermo Scientific, Waltham, 
USA 
Penicillin/streptomycin P06-0700 PAN™ biotech, Passau, GER 
Ponceau-S P7170 Carl Roth, Karlsruhe, GER 
Sodium dodecyl sulfate (SDS) 4360.2 Carl Roth, Karlsruhe, GER 
Sodium Pyruvate P04-43100 PAN™ biotech, Passau, GER 
Sucrose 4661.1 Carl Roth, Karlsruhe, GER 
   
Tetramethylethylenediamine 
(TEMED) 







T7394 Sigma, St. Louis, USA 
Trehalose 5151.3 Carl Roth, Karlsruhe, GER 
Tris 54292 Carl Roth, Karlsruhe, GER 
Triton X-100 3051.4 Carl Roth, Karlsruhe, GER 
Trizol 15596026 Invitrogen, Darmstadt, GER 
Trypsin/EDTA P10-023100 PAN™ biotech, Passau, GER 
XF-calibration medium 100840-000 Seahorse Bioscience, North 
Billerica, USA 
 
2.6. Chemical inhibitors 
The chemical inhibitors used in this project are given in Table 6.  












347795 Sigma, St. Louis, USA 5 mM 
Oligomycin 495455 Calbiochem, San Diego, USA 1.5 -3 µM 
FCCP C2920 Sigma, St. Louis, USA 1 µM 
Rotenone R8875 Sigma, St. Louis, USA 2 µM 
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Antimycin A A8675 Sigma, St. Louis, USA 1 µM 
2-deoxyglucose (2-
DG) 
D6134 Sigma, St. Louis, USA 100 mM 
 
2.7. Buffers and solutions 
The buffers and solutions are given in Table 7. 
Table 7: Buffers and solutions 
Liquids Recipe/Manufacturer 
2x Laemmli buffer 100 mM Tris/HCl, pH 6.8  
4% SDS  
0.2% bromphenol blue  
20% glycerol  
5% β-mercaptoethanol  
Lysis buffer 50 mM Tris 
150 mM NaCl 
5 mM PMSF 
100 mM MgCl2 
1% Igepal 
ECL 100 mM Tris/HCl, pH 8.5  
90 mM coumaric acid  
250 mM luminol  
0.009% H2O2  
PBS (Phosphate Buffered Saline)  137 mM NaCl  
2.7 mM KCl  
4.3 mM Na2HPO4·7H2O  
1.4 mM KH2PO4, pH 7.4  
TBS-T 20 mM Tris 
150 mM NaCL 
0.1% (v/v) Tween-20 
pH 7.6 
Running buffer (1x) 125 mM Tris  
1.25 M glycine  
0.5% SDS 
Transfer buffer (1x) 25 mM Tris  
192 mM glycine  
20% (v/v) methanol  
Developer Tetanal (Roentogen) 
1:3.5 
Fixer Tetanal (Roentogen Superfix) 




THE buffer 300 mM trehalose  
10 mM HEPES  
10 mM KCL  
1 mM EDTA  
1 mM EGTA  
pH 7.7 
MAS buffer 70 mM sucrose 
220 mM mannitol 
2 mM HEPES 
10 mM KH2PO4 
5 mM MgCl2 
1 mM EGTA 
0.2% BSA  
pH 7.4 
prepare fresh 
Alkaline tail lysis buffer 25 mM NaOH 
0.2 mM EDTA 
DCF-assay buffer 20 mM Tris 
150 mM NaCl 
0.1 % Triton pH 7.4 
 
2.8. Media 
The media used are given in Table 8. 
Table 8: Media 
Liquids Recipe/Manufacturer 
DMEM-Cell Culture Medium DMEM High Glucose (4.5 g/L) (PAA, 
Pasching AUS) 
10% (v/v) heat-inactivated FCS  
100 U/mL penicillin G 
100 μg/mL streptomycin 
200 mM L-glutamine 
Complete culture medium (BMDM) DMEM High Glucose (4.5 g/L) (PAA, 
Pasching AUS) 
10% (v/v) heat-inactivated FCS  
200 mM L-glutamine  
1 mM sodium pyruvate,  
1 mM HEPES,  
50 U/mL penicillin G, 50 μg/mL 
streptomycin  
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Pluznik medium DMEM High Glucose (4.5g/L) (PAA, 
Pasching AUS) 
10% (v/v) heat-inactivated FCS 
0.2 mM L-glutamine  
0.1 mM sodium pyruvate 
50 U/mL penicillin G, 50 μg/mL 
streptomycin  
5% (v/v) heat-inactivated horse serum  
0,05% 1:1000 diluted ß-mercaptoethanol 
15% (v/v) L929 cell-conditioned medium 
XF-assay medium XF assay medium (Seahorse Bioscience, 
North Billerica, USA) 
1 mM sodium pyruvate 




DMEM D 5030 (Sigma, St. Louis, USA) 
134 mM NaCl 
3 mg phenol red 




The antibodies used in this project are listed in Table 9. 
Table 9: Antibodies 
Antibody Source Catalog number Provider Dilution 
Primary Antibodies 
anti-β-actin mouse A5441 Sigma, St. 
Louis, USA 
1:100000 
anti-HIF-1α rabbit NB-100-479 Novus , 
Colorado, USA 
1:1000 
anti-PHD2 rabbit NB 100-2219 Novus , 
Colorado, USA 
1:500 










) rabbit ABS204 Merck 
Millipore, 
1:10000 


























Oligonucleotides listed in Table 10 were purchased at Biomers, Ulm, GER 
 
Table 10: Oligonucleotides 
Gene Oligonucleotide 
qPCR  
ms12 forward 5´-GAAGCTGCCAAGGCCTTAGA -3´ 
reverse 3´-AACTGCAACCAACCACCTTC -5´ 
PHD2 forward 5´- TTGCTGACATTGAACCCAAA -3´ 
reverse 3´- GGCAACTGAGAGGCTGTAGG -5´ 
PHD3 forward 5´-GGCCGCTGTATCACCTGTAT -3´ 
reverse 3´-TTCTGCCCTTTCTTCAGCAT -5´ 
GLUT1 forward 5´- TGGCCTTGCTGGAACGGCTG -3´ 
reverse 3´- TCCTTGGGCTGCAGGGAGCA -5´ 
PFK1 forward 5´- ACGAGGCCATCCAGCTCCGT -3´ 
reverse 3´- TGGGGCTTGGGCAGTGTCCT -5´ 
PDK1 forward 5´- TTCACGTCACGCTGGGCGAG -3´ 
reverse 3´-GGCTGGGCACACACCAGTCG -5´ 
Cox4-2 forward 5´-CAGAGAAGGTGGCCTTGTACC -3´ 
reverse 3´-AGAAGAAGACGCAGCCCATC -5´ 
LonP forward 5´-CATCGCCTTGAACCCTCTGT -3´ 
reverse 3´-AGCCGCTTAAGGATGTTGGT -5´ 
BNIP3 forward 5´-GTCCAGTGTCGCCTGGCCTC -3´ 
reverse 3´-TGGGAGCGAGGTGGGCTGTC -5´ 
Genotyping 
Cre forward 5´- GTTCGCAAGAACCTGATGGACA -3´ 
reverse 3´-CTAGAGCCTGTTTTGCACGTTC -5´ 
PHD2 
flox 
forward 5´- CTCACTGACCTACGCCGTGT -3´ 
reverse 3´-CGCATCTTCCATCTCCATTT -5´ 
  Materials and Methods 
26 
 
2.11. Ready-to-use reaction systems 
The ready to use reaction systems listed in Table 11 were utilized in this work. 
Table 11: Ready-to-use systems 
Description Order number Manufacturer 
L-lactate kit 10139084035 R-Biopharm, Darmstadt, GER 
First Strand cDNA synthesis kit K1612 Fermentas St. Leon-Rot, GER 
SensiMix™ SYBR® Low-ROX 
Kit 
QT625-05 Bioline, Luckenwalde, GER 
CellTiter-Glo® Luminescent 
Viability Assay 
G7570/7571 Promega, Madison, USA 
Pyruvate dehydrogenase-
activity kit 
MAK183 Sigma, St. Louis, USA 
 
2.12. Mouse model 
Primary bone marrow derived macrophages were obtained from a myeloid specific PHD2 




, PHD2 cKO) (obtained from Ben Wielockx, 
TU Dresden, described in (Singh et al., 2013)). PHD2
fl/fl
 mice that contain LoxP sites flanking 
exon 2 and 3 were crossed with mice that express the Cre recombinase under the control of 
the endogenous lysozyme M locus (LysMCre) (Jackson Laboratories, Maine, USA, described 
in (Clausen et al., 1999)). Cre-mediated recombination then resulted in deletion of PHD2 in 
the myeloid cell lineage, including monocytes, macrophages, granulocytes and in part 
dendritic cells (Clausen et al., 1999). 
 
Figure 5: Crossing scheme PHD2fl/fl mice that contain LoxP sites flanking exon 2 and 3 were crossed with mice that express 
the Cre recombinase under the control of the endogenous lysozyme M locus (LysMCre). 
  




2.13. RAW cell line with constitutively active shRNA targeting PHD2 
The shPHD2 cell line was generated and kindly provided by Dr. B. Wielockx, Institute of 
Pathology, TU Dresden. RAW 264.7 cells were infected with a lentivirus encoding shRNA 
targeting mPHD2 (5’-ATTCGAAGAATACCTCCAC-3’). The cells were then used as a pool 
of sorted EGFP positive
 
cells. Knockdown efficiency was determined by qPCR. 
 
2.14.  Cell biology 
2.14.1. Cell culturing  
Cells were cultivated in high glucose DMEM medium supplemented with 100 U/mL 
penicillin G, 100 μg/mL streptomycin and 10% heat-inactivated fetal calf serum. The cells 
were kept at 37°C, 5% CO2 and split every second day in a ratio depending on the observed 
cell proliferation (mostly in a ratio of 1:10) using a cell scraper. For experiments performed in 
hypoxia, cells were kept for 24 h at 37°C at 1% oxygen using the In Vivo2 400 work station. 
L929 cells and MDA-MB 231 cells were detached using trypsin. The density of cells was 
determined using a Neubauer counting chamber. The cell number was determined by counting 
the average cell number of each large square x10
4 
x dilution factor.  
To freeze cells, cells were sedimented and resuspended in 1 ml freezing medium (FCS 
supplemented with 10% DMSO). Cells were frozen in cryoboxes containing isopropanol to 
obtain a constant cooling of approximately 1°C per minute. To cultivate cells from a frozen 
aliquot, defrosted cells were washed with 20 ml of the respective medium and sedimented by 
centrifugation at 450 xg, 5 min at RT. The cell pellet was resuspended in 15 ml medium and 
cells were incubated at 37°C, 5% CO2 in flasks. 
2.14.2.  Preparation of MDA-MB 231 conditioned medium 
5 flasks with each 1x10
6 
cells were cultivated in 15 ml complete culture medium for 4 days. 
The medium was transferred to a reaction tube and centrifuged at 4000 xg for 20 min at 4 ºC. 
The supernatant was pooled and frozen in 4 mL aliquots at -80 ºC. 
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2.14.3.  Preparation of L929 conditioned medium (Pluznik) 
4x10
6
 L929 cells were seeded in 50 ml complete culture medium in a T75 flask. After 7 days, 
the supernatant was taken, centrifuged at 4000 xg, for 20 min and filter-sterilized before being 
stored at -20 ºC.  
2.14.4. Differentiation and cultivation of bone marrow-derived macrophages 
(BMDM)  
BMDM are primary macrophages isolated from the bone marrow and differentiated in vitro in 
the presence of macrophage colony-stimulating factor (M-CSF). M-CSF is a growth factor 
which is important for the proliferation and differentiation of macrophages. In this protocol, 
the conditioned medium of L929 cell was used as a source of M-CSF (protocol adapted from 
(Weischenfeldt and Porse, 2008)).  
8 to 12 weeks old wild type and PHD2 cKO
 
mice were killed by cervical dislocation and the 
femur was isolated from both legs. Bone marrow cells were isolated by flushing the femur 
with a 26 gauge needle and cultured on surface-treated cell culture dishes in complete culture 
medium (DMEM supplemented with, 0.2 mM L-glutamine, 0.1 mM sodium pyruvate, 1 mM 
HEPES, 50 U/mL penicillin G, 50 μg/mL streptomycin and 10% heat-inactivated fetal calf 
serum) at 37°C and 5% CO2. After 24 h, non-adherent monocytes were harvested and 
distributed on non-surface-treated cell culture dishes in 10 ml Pluznik´s medium (DMEM 
supplemented with, 0.2 mM L-glutamine, 0.1 mM sodium pyruvate, 50 U/mL penicillin G, 50 
μg/mL streptomycin 10% heat-inactivated fetal calf serum, 5% heat-inactivated horse serum , 
0,05% 1:1000 diluted ß-mercaptoethanol and 15% L929 cell-conditioned medium) and 
differentiated for 7 days. On day 3, the Pluznik´s medium was refreshed. On day 7 of 
differentiation, the bone marrow-derived macrophages (BMDM) were detached using 3.5 mL 
accutase and seeded for experiments in complete culture medium.  
2.14.5. Efficiency of BMDM differentiation 
BMDM differentiation was checked by analysing F4/80 surface antigen expression using flow 
cytometry (described in (Weischenfeldt and Porse, 2008)). Cells were detached on day 7 of 
differentiation using accutase. 0.66 x10
6 
cells were stained with F4/80-PE labeled antibody for 
  Materials and Methods 
29 
 
20 min in the dark. The cells were washed with PBS and F4/80 expression was analyzed 
using flow cytometry. 
2.14.6. Isolation and cultivation of murine peritoneal macrophages 
8 to 12 weeks old wild type and PHD2 cKO
 
mice were killed by cervical dislocation. The 
abdomen was incised without harming the peritoneal cavity. The skin was pulled to the top to 
show the lining of the peritoneal cavity. The peritoneal cavity was injected with 4 mL of PBS 
supplemented with 0.5 % BSA, 2 mM EDTA using a 26 gauge needle. Then, the abdomen 
was massaged in order to detach cells and with the help of a 25 gauge needle, the cell-
containing PBS was collected. Subsequently, cells were centrifuged at 400 xg for 10 min at 
4ºC, washed once with medium and seeded in 6-well plates. After 2 h, cells were washed 
twice with medium and cultured in complete culture medium. FACS analysis was performed 
to estimate the purity of the obtained peritoneal macrophages (see chapter 2.14.5.) 
2.14.7.  Mitochondrial preparation 
5x10
7
 cells were washed twice with PBS and harvested in PBS. The cells were sedimented at 
1000 xg for 10 min and the pellet was resuspended in 2 ml THE buffer (300 mM Trehalose, 
10 mM HEPES, 10 mM KCL, 1 mM EDTA, 1 mM EGTA, pH 7.7) supplemented with 0.1% 
BSA, 1 mM PMSF and 1% protease inhibitor and homogenized for 25 times in a 2 ml potter, 
After a centrifugation step of 10 min at 400 xg at 4ºC, the supernatant was transferred to a 
new Eppendorf tube and the process was repeated 3 times. Then, the collected supernatant 
was centrifuged for 7 min at 800 xg and transferred to a fresh 1.5 ml Eppendorf tube. To 
pellet the mitochondria, the samples were centrifuged at 11 000 xg for 10 min and the 
mitochondrial pellet was resuspended in 50 µL THE-buffer without BSA. The protein 
concentration was determined by Bradford assay and diluted to a concentration of 10 µg/µL. 
Mitochondria were either used directly or frozen in liquid nitrogen and then stored at -80 ºC 
for later use.  
2.14.8.  Determination of Lactate levels in BMDM and RAW supernatant 
For the determination of L-lactate levels, a L-lactate kit was used according to the 
manufacturer’s instructions (R-Biopharm). This kit uses the ability of nicotinamide-adenine 
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dinucleotide (NAD) to oxidize L-lactate to pyruvate in the presence of L-lactate 
dehydrogenase (L-LDH) (I).  
(I) 
  
However, the equilibrium of this reaction (I) lies in the favor of L-lactate and NAD
+
. Hence, 
the pyruvate needs to be trapped. This is achieved using the enzyme glutamate-pyruvate 
transaminase (GPT). This enzyme converts pyruvate to D-alanine and α-ketoglutarate in the 
presence of L-glutamate (II). 
(II) 
 
The amount of NADH produced is stoichiometric to the amount of L-lactate in the sample. 
The increase of NADH was measured spectrophotometrically at 340 nm.  
 0.75 x 10
5
 BMDM and RAW cells were cultivated for 24 h in 24-well plates in a volume of 
500 µL per well. The supernatant was centrifuged at 16 000 xg for 30 min, 4 ºC to remove 
cellular debris. 100-150 µL of the supernatant was used for the reaction. An equal amount of 
medium was used as a blank. The sample was well mixed with the reaction buffer containing 
10 ml solution 1 (glycylglycine buffer, pH 10; L-glutaminic acid, ca 440 mg), 0.2 ml solution 
2 (210 mg NAD-lyophilisate), 0.02 ml solution 3 (Glutamate-pyruvate-transaminase-
suspension (1100 U)) and 0.9 ml of distilled water. After 5 min, the extinction was measured 
at 340 nm (E1). Then, 0.02 ml L-lactate-dehydrogenase-solution were added (3800 U) and 
mixed. After 30 min, the reaction was terminated and the samples were mixed and measured 
again (E2). The extinction difference was calculated (E2-E1).  
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The concentration was calculated using the following formula:  
C=
    
          
x ΔE (g/L) 
 
V = test volume (ml) 
v = sample volume (ml) 
MG = molecular weight of substance (89.1 g/mol for L-Lactate) 
D = light path (1 cm) 
Ε = extinction coefficient of NADH at 340 nm=6.3 l/mmol x cm 
2.14.9.  Measurement of PDH activity 
For the determination of the PDH activity, a kit was used according to the manufacturer’s 
instruction with slight modifications (Sigma-Aldrich). PDH activity was determined in a 




cells per plate were seeded 24 h prior to the experiment and treated with the 
respective inhibitors. The day of the experiment the cells were washed with PBS and 
harvested in 200 µL ice-cold PBS. The cells were then spun down at 10 000 xg for 5 min and 
washed two more times with PBS before being homogenized in 150 µL ice-cold PDH assay 
lysis buffer. After an incubation time of 10 min, the samples were centrifuged at 10 000 xg for 
5 min. The supernatant was transferred to a fresh tube. For determination of NADH 
generation, a NADH standard curve was pipetted in a 96 well plate (0, 2.5, 5, 7.5, 10, 12.5 
nmol/well). 25 µL of the samples were used in the assay and each well was filled up to a total 
volume of 50 µL with PDH assay buffer. In parallel, the reaction mix was prepared as 
described in Table 12. 
Table 12: Composition of the reaction mix 
Reagent Standards and samples 
PDH assay buffer 46 µL 
PDH developer 2 µL 
PDH substrate 2 µL 
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50 µL of the reaction mix was added to each well and mixed well using a horizontal shaker. 
The plate was incubated at 37ºC and initially measured after 5 min (Tinitial) at 450 nm. The 
plate was continued to be incubated at 37ºC with measurements every 5 min until the first 
value of the most active sample exceeded the highest value of the NADH standard curve. At 
this time, the most active sample is near or higher than the end of the linear range of the 
standard curve. Therefore, the second to last reading was used for calculating the enzyme 
activity (Tfinal). First, the initial measurements (Tinitial ) were subtracted from the final readings 
(Tfinal).  
Sa(ΔA450) = (A450) final – (A450) initial. 
With the corrected measurements, the amount of NADH (nmol/well) produced by the PDH 
assay was calculated between Tinitial and Tfinal (Sa). 
             
  
                  
 
With: 
Sa = amount of NADH (nmol) generated in unknown sample well between Tinitial and Tfinal from standard curve 
Reaction Time = Tfinal – Tinitial (min) 
Sv = sample volume (mL) added to well  
 
The activity of PDH was reported as nmol/min/mL= milliU/mL. One unit is defined as the 
amount of enzyme needed to generate 1µmol of NADH per min at 37 ºC. 
Additionally, the protein concentration of the samples was determined by Bradford assay and 
used for normalization. 
2.14.10.  ATP levels 
For measurements of cellular ATP levels, 0.25 x 10
5
 BMDM or RAW cells were seeded in 
100 µL culture medium in 96-well luminometer plates for cell culture and measured 24 h later 
using the ATP kit according to the manufacturer´s instructions with slight adaptations 
(Promega). The Cell titer-Glo® Assay relies on the properties of thermostable luciferase 
which converts beetle luciferin to oxyluciferin in the presence of ATP. After pipetting an ATP 
standard curve to each plate and after adding the lysis buffer, cells were kept at 37 
◦
C for 5 
min to allow cells to lyse before taking them out of the hypoxia chamber or the incubator. The 
plates were incubated for 30 min on a shaker, then assayed in a luminometer plate reader and 
normalized to protein content as determined by Bradford assay. 
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2.14.11.  Seahorse measurements 
2.14.11.1.  Measurement of oxygen consumption rate of total cells using the Seahorse 
XF96 analyzer 
The Seahorse XF96 analyzer (SeahorseBioscience) was used to determine the oxygen 
consumption rate (OCR). This is done by measuring the quenching of an oxygen-sensitive 
fluorophore. The Seahorse XF96 analyzer can be used to assess cellular functions such as 
oxidative phosphorylation by metabolically disturbing the cells. The first addition is 
oligomycin. Oligomycin blocks the proton channel of the ATP synthase thereby inhibiting 
ATP synthesis. It is used to distinguish between the OCR used for ATP synthesis and OCR 
needed to overcome the natural proton leak across the inner mitochondrial membrane.  
The second addition is FCCP. FCCP is used as an uncoupling agent. It transports protons 
across the mitochondrial membrane. This disrupts the mitochondrial membrane potential 
leading to a fast increase in OCR without producing ATP. Thus, FCCP is used to determine 
the maximal respiratory capacity of the cells.  
The third addition is the combination of the complex I inhibitor rotenone and the complex III 
inhibitor antimycin A. Rotenone inhibits the transfer of electrons from complex I to 
ubiquinone. Antimycin A binds to the cytochrome c reductase. This way, the oxidation of 
ubiquinol is prevented. As a result, mitochondrial respiration is arrested. The residual 
respiration is of non-mitochondrial origin and needs to be deducted from the rest of the 
measured rates.  
2.5 x 10
4 
RAW or 4.0 x 10
4 
BMDM cells per well were seeded the day prior to the experiment 
in a XF96 cell culture microplate in the respective cell culture medium. The XF sensor is 
hydrated with XF Buffer at 37ºC without CO2 overnight. At the day of the experiment, the 
injection ports of the XF-sensor cartridge were loaded with the compounds noted in Table 13 
and the sensor cartridge was placed in the XF96 analyzer for calibration. 
  




Table 13: Concentration of compounds 
Port Reagent Concentration (final) 
A XF-assay medium n/a 
B oligomycin 1.5 µM 
C FCCP 1 µM 
D rotenone  2 µM 
antimycin A 1 µM 
 
In parallel, the medium of the XF cell culture microplate was replaced with XF assay medium 
supplemented with 4.5 g/L Glucose and 1 mM sodium pyruvate and incubated at 37 ºC 
without CO2 for 30 min. Oxygen consumption was measured using the protocol shown in the 
Table 14. 
Table 14: Measurement protocol for OCR 






























2.14.11.1. Measurement of the extracellular acidification rate using Seahorse XF96 
analyzer 
The conversion of glucose to pyruvate and subsequently to lactate results in the production 
and extrusion of protons. This leads to the acidification of the medium. This acidification can 
be measured by the XF96 analyzer and is reported as extracellular acidification rate (ECAR) 




– 4 x 10
4
 
(BMDM) cells per well. The next day, the cells were washed 10 times with XF Glycostress-
medium (DMEM D 5030, 134 mM NaCl, 3 mg Phenol Red, 2 mM L-glutamine, pH 7.35). 
XF-Glycostress-medium does not contain either glucose or pyruvate, but only 1 mM L-
Glutamine. The cells were incubated in 180 µL of XF Glycostress-medium for 15 min at 
37 ºC without CO2. In parallel, the XF sensor cartridge was prepared. The protocol used for 
the XF measurement is shown in Table 15. 
The first addition is a saturating concentration of 10 mM freshly prepared glucose. The cells 
use the injected glucose and catabolize it using the glycolytic pathway leading to an increase 
in proton production. This causes an increase in the ECAR. This glucose-induced response is 
referred to as the glycolytic rate under basal conditions. The second addition is 1.5 µM (for 
RAW cells) or 3 µM (for BMDM) oligomycin. Oligomycin blocks the mitochondrial ATP 
production which causes a shift of the energy production in favor of glycolysis. This rapidly 
increases the ECAR and reveals the maximal glycolytic capacity of the cell. The last addition 
is 100 mM of the glucose analogue 2-deoxy-glucose (2-DG). 2-DG inhibits glycolysis 
because of its competitive binding to glucose hexokinase. This results in a decrease in ECAR 
and confirms that the ECAR measured in the experiment is in fact due to glycolysis.  
Table 15: Measurement protocol for ECAR 
Command  Time (min) 
calibrate  -- 
equilibrate  -- 
loop 3 times mix 2 min 
 measure 4 min 
loop end   
Inject port A 
loop 3 times mix  2 min 
 measure  4 min 
loop end   
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Inject port B 
loop 3 times mix 2 min  
 measure 4 min 
loop end mix 2 min 
Inject port C 
loop 3 times   
 measure 4 min 
loop end    
Program end   
2.14.12. Measurement of phagocytosis by flow cytometry 
Phagocytic capacity was determined by investigating the uptake of fluorescent beads by flow 
cytometry. Flow cytometry is based on the detection of fluorescence emitted by a single cell 
flowing through a liquid stream (described in (Jaroszeski and Radcliff, 1999). A laser beam of 
a specific wavelength is pointed to the liquid stream. Several detectors are placed at the point 
where the stream passes the laser beam. One detector is in line with the laser beam and 
provides information about the Forward Scatter (FSC) of the cell and several others are placed 
vertically to it measuring the Side Scatter (SSC). Every cell that passes the laser beam scatters 
the light. The FSC depends on the cell volume and the SSC correlates with the inner 
complexity (or granularity) of the cell. Furthermore, there are also fluorescent detectors which 
detect fluorescence emitted by the cell. For the detection of phagocytosis, phycoerythrin 




 RAW cells or 0.66 x 10
6  
BMDMs were seeded in 3.5 cm dishes and incubated at 
normoxic and hypoxic conditions overnight. RAW cells were seeded on cell culture-treated 
plates and BMDM on non-surface-treated plates. Fluorescent beads were added to the cells 
and incubated for 4 h. RAW cells were detached using dispase and BMDMs using accutase. 
Cell were washed twice with PBS and then analyzed by flow cytometry.  
2.14.13. Measurement of reactive oxygen species (ROS) by H2-DCF 
For the determination of mitochondrial reactive oxygen species (ROS), 150 µg isolated 
mitochondria were measured in 500 µL assay buffer (20 mM Tris, 150 mM NaCl, 0.1 % 
Triton, pH 7.4) with 200µM 2´,7´-dichlorodihydrofluorescein diactetate (H2DCFDA) at 37 ºC 
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in a Hitachi F-7000 fluorimeter with an excitation wavelength of 495 nm and an emission 
wavelength of 525 nm for 1000 sec. H2DCFDA is non fluorescent , but when oxidized it is 
converted to the fluorescent 2´,7-dichlorofluorescin (DCF). Basal reading (buffer only) was 
subtracted from the other measurements and fluorescence was depicted as arbitrary units 
(a.u.). 
2.14.14. Measurement of reactive oxygen species by DHE-HPLC 
Dihydroethidium (5-ethyl-5,6-dihydro-6-phenyl-3,8-diaminophenanthridine, DHE) is an 
hydrophobic uncharged compound which becomes positively charged upon oxidation. It 
intercalates with the DNA of the cells. Determination of DHE fluorescence can be used as a 
measure for reactive oxygen species (ROS) in cells. DHE can be oxidized to two different 
products (2-hydroxyethidium (EOH) and ethidium). These products can be separated by 
DHE-HPLC (protocol adapted from (Laurindo et al., 2008). Cells were washed two times 
with PBS and incubated with 100 µM DHE for 30 min in 500 µL PBS + 0.1 mM DPTA. The 
cells were then harvested in 500 µL cold acetonitrile and sonicated for 10 s, 1 cycle at 6-8 W. 
Acetonitrile is an organic solvent which efficiently breaks the interaction of DHE products 
and DNA. Then, the cell lysates were spun at 12 000 xg for 10 min at 4°C. After that, 
supernatants were dried under vacuum. Pellets were either stored at -20 ºC in the dark or 
directly re-suspended for measurement in 80 µL PBS + 0.1 mM DTPA. Samples were 
analyzed by high performance liquid chromatography (HPLC). 2-hydroxyethidine (EOH) and 
ethidium were separated using a Kromasil C18 column (particle size: 5 µm, dimensions: 
4.6 x 250 mm) in a HPLC system containing a photodiode array and fluorescence detectors. 
30 µL of each sample was injected. EOH and ethidium was identified detecting fluorescence 
at an excitation wavelength of 510 nm and an emission wavelength of 595 nm. A gradient of 
solution A (pure acetonitrile) to solution B (water/ 10 % acetonitrile/ 0.1 % trifluoroacetic 
acid, v/v/v) were used at a flow rate of 0.4 ml/min. Runs started with 0 % solution A, then this 
is increased up to 40% solution A during the first 10 min. This condition was maintained for 
10 more min and then changed to 100 % solution A for additional 5 min and 0 % solution A 
for 10 min. The unoxidized DHE was measured by UV absorption at 245 nm. Therefore, the 
remaining DHE was subtracted from the initial DHE concentrations. DHE-products were 
expressed as ratios of EOH and ethidium generated per consumed DHE (EOH/DHE and 
ethidium/DHE).  
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2.14.15. Cell proliferation assay 
2 x 10
4 
cells per cell line were seeded in 2 ml in 3.5 cm dishes. Cells were detached by 
thorough scraping at day 1, 3, 5 and 7 after being seeded. Viable cells were stained using 
trypan blue and counted using a Neubauer chamber. When reaching a seeding density of ca 
70%, cells were transferred to a 6 cm dish and subsequently a 10 cm dish. The cell doubling 
time (DT) was calculated using the formula: 
DT=
                    
                    
 
d= days 
Nfin = cell number at the end of the experiment 
Ninit = cell number at the beginning of the experiment 
  
2.14.16. Migration assays 
2.14.16.1.  Boyden chamber 
The Boyden chamber assay is based on a chamber of two compartments that are separated by 
a microporous membrane (described in (Chen, 2005)). The cells are placed in the upper 
compartment. In the lower compartment a chemotactic stimulus is present. The cells can 
migrate from the upper compartment to the lower compartment toward the chemotactic 
stimulus. In this study, the supernatant of MDA-MB 231 cells, a breast cancer cell line, was 
used as a migration stimulus. 
 0.7 x 10
5
 BMDM and RAW cells were placed in a cylindrical cell culture insert with a pore 
size of 3 µm (BD Biosciences) in a volume of 500 µL in a 24 well plate. In the well below, 
the supernatant of MDA-MB 231 cells was placed. After 18 h, the cells which migrated to the 
lower chamber were stained with 5 µM calcein (Sigma, St. Louis, USA) and the cells from 
the upper chamber were gently removed using a cotton swab. Transwell-migration was 
analyzed by microscopy at 10x magnification. 7 images from each upper edge to the lower 
edge of the wells were taken. For analysis, the images at the edges were excluded and only the 
5 middle images were used. The amount of migrated cells was analyzed using the “find 
maxima”-function of ImageJ. 
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2.14.16.2. Single cell migration 
2.5 x 10
4  
RAW cells and 5 x 10
4  
BMDMs were seeded in a 6 well plate in 2 ml. The next 
day, the medium was replaced with either normal cell culture medium or MDA-MB 231 
conditioned medium. The migration of the cells was investigated using the T1-5M Nikon 
microscope inside the Sci-tive box at normoxic or hypoxic conditions. An image was taken 
every 10 min for 6 h. The migration was analyzed using the manual tracking plugin 
(http://rsb.info.nih.gov/ij/plugins/manual-tracking.html) and chemotaxis  plugin  
(http://ibidi.com/software/chemotaxis_and_migration_tool/)  installed in ImageJ.  
 
2.15.  Molecular biology 
2.15.1. Genotyping 
Small pieces of mouse ear or tail were placed into 75 µL of alkaline lysis buffer (25 mM 
NaOH, 0.2 mM EDTA). For the genomic DNA (gDNA) of RAW cells and BMDMs, 
0.75 x 10
6
 cells were lysed in 75 µL alkaline lysis buffer. Then the samples were incubated 
for 1 hour at 95°C to lyse the tissue. The samples were transferred to 4°C for 10 min. 
Subsequently, 75 μl of 40 mM Tris/HCl buffer was added. 1 μl of each sample was used for 
the PCR reaction. gDNA isolated from RAW cells and BMDMs was used for qPCR (see 
chapter 2.15.4). The protocol for genotyping is found in Table 16. The primers used for 
genotyping can be found in Table 16.  
Table 16: Genotyping PCR 
 Cre PHD2 flox  
Step Temperature Time Temperature Time Repeats 
Initial 
denaturation 
94 ºC 240 sec 94 ºC 120 sec 1 cycle 
Denaturation 94 ºC 30 sec 94 ºC 15 sec 30 cycles 
Annealing 60 ºC 30 sec 53 ºC 25 sec 
Elongation 72 ºC 75 sec 72 ºC 30 sec 
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2.15.2. RNA extraction 
For RNA isolation 0.75 x 10
6
 BMDM or 0.66 x 10
6
 RAW cells were washed twice with PBS 
and harvested in 500 µL Trizol (Invitrogen). Then, 100 µL chloroform  was added, vortexed 
and kept at RT for 5 min. After a centrifugation step of 12 000 xg for 10 min at 4ºC, the upper 
layer (aqueous phase) was transferred to a fresh Eppendorf tube with 250 µL of isopropanol. 
After 10 min of incubation at RT, the eppendorf tubes were centrifuged at 12 000 xg for 10 
min, 4ºC. This was followed by two washing steps with 500 µL and 750 µL 75% EtOH. After 
centrifugation for 10 min at 12 000 xg, 4ºC, the supernatant was removed and the pellet left to 
dry for 10 min with the lid of the Eppendorf cup opened. Then 15 µL (for RNA from BMDM) 
or 40 µL (for RNA from RAW cells) of nuclease-free water was added and the pellet was 
resolved for 10 min at 56ºC. Afterwards, the samples were either frozen at -80ºC or used 
directly for cDNA synthesis. 
2.15.3.  cDNA-Synthesis 
cDNA is a DNA copy that is synthesized from messenger RNA (mRNA) (reviewed in 
(Harbers, 2008). This reaction is mediated by a reverse transcriptase, which is a retroviral 
RNA-dependent DNA polymerase. As a starting point for synthesis, the poly (A) tail found at 
the 3´-end of most eukaryotic mRNA is used. To generate a starting point, a short 
complementary synthetic oligonucleotide (Oligo-dT primer) is hybridized. Using the four 
deoxynucleotide triphosphates and in the presence of magnesium ions and at a neutral pH, the 
reverse transcriptase synthesises complementary DNA from the original mRNA. 
2 µg RNA was transcribed with the First Strand cDNA Synthesis Kit (Fermentas). For cDNA 
synthesis, the RNA was prepared in a volume of 11 µL together with 1 µL Oligo-dT-Primer 
and incubated at 65ºC for 10 min. The samples were chilled on ice for 5 min, shortly spun 
down and placed back on ice. Then 9 µL reaction buffer was added (containing 4 µL 5x 
Reaction buffer, 1µL RiboLock RNase Inhibitor (20 U/µL), 2 µL 10mM dNTP-Mix and 2 µL 
M-MuLV Reverse Transcriptase (20 U/µL)). After gentle mixing and centrifugation, the 
samples were incubated for 60 min at 37 ºC. The reaction was terminated by heating at 70 ºC 
for 5 min. The synthesized cDNA was either used directly or stored at -20 ºC.  
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2.15.4. Transcript quantification by qRT-PCR (quantitative Real-Time-Polymerase 
Chain Reaction) 
Quantitative Real-Time-PCR can be used to amplify and quantify simultaneously a targeted 
DNA sequence in a double stranded DNA molecule (reviewed (Wilhelm and Pingoud, 2003). 
It uses primer pairs of each about 20 nucleotides in length that are complementary to the 
targeted sequence on each of the two strands of the DNA. A DNA polymerase binds to the 
annealed primers copying the targeted sequence. After copying, the primers bind to the 
originally DNA molecule as well as to the newly synthesized copy. This leads to an 
exponential amplification. SYBR® Green is an asymmetrical cyanine dye which is used as a 
nucleic acid stain because of its binding affinity to double stranded DNA (dsDNA). The 
SYBR® Green-dsDNA complex absorbs blue light at a wavelength of λmax=488 nm and emits 
green light at a wavelength of λmax=522 nm. This property can be used to detect double-
stranded PCR products during the PCR reaction. As a reference dye, ROX™ was used to 
normalize the fluorescence between the reactions. The number of PCR cycles that show a 
significant exponential increase in fluorescence correlates with the amount of copied DNA 
templates. This is referred to as Cycle Threshold (CT).  
Transcript quantification was carried out with SensiMix™ SYBR® Low-ROX Kit (Bioline). 
The PCR reaction was performed using MX3005Pro light cycler sequence detection system. 
For each qRT PCR-reaction, 12.5 µL SYBR® GreenMix was used and an amount of cDNA 
corresponding to 10 ng RNA (1 µL) and 400 nM forward and reverse primer in total reaction 
volume of 25 µL. PCR reactions were performed either in a 96 well plate sealed with an 
optical adhesive foil or in PCR reaction tubes. The reaction was performed using the protocol 
in Table 17. The Tm value differs because it depends on the melting temperature of the PCR 
product. The Tm is defined as the temperature where 50% of the helices are dissociated 
because the DNA helix melts in a temperature range rather than at one specific temperature.  
  




Table 17: qPCR protocol 
Step Temperature Time Repeats 
Initial denaturation 95 ºC 10 min 1 cycle 
Denaturation 95 ºC 30 sec 40 cycles 
Annealing Tm ºC 20 sec 
Extension 72 ºC 30 sec 
Dissociation stage 95 ºC 60 sec 1 cycle 
Tm ºC 30 sec 
95 ºC 30 sec 
 
The primer sequences used are listed in Table 10. 
The relative expression value of each gene was estimated by normalization of the probe CT 
values to CT values of the housekeeper gene mouse ribosomal protein S12 (ms12).  
ΔCT= CTgene of interest- CT housekeeping gene    
The control and modified samples can be compared by calculating ΔΔCT values. ΔΔCT 
indicates the difference of cycles between the modified and the control condition. The ΔΔCT 
is used to calculate the normalized gene expression level (2 
–ΔCT
). This can be used to 
calculate the fold change of the modified sample compared to the mean of the control 
condition. 
For the determination of the mitochondrial content, a standard curve for the nuclear genomic 









 copies) was included.  
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2.16. Protein biochemistry 
2.16.1. Protein extraction 
Cells were washed twice with ice-cold PBS and then lysed in protein lysis buffer (50 mM 
Tris, 150 mM NaCl, 5 mM PMSF, 100 mM MgCl2, 1% Igepal) containing protease inhibitor 
cocktail cOmplete Mini. For the detection of phosphorylated protein, the phosphatase 
inhibitor cocktail PhosStop was used. The cells were detached from the plates using a cell 
scraper and incubated on ice for 10 min. The extract was centrifuged for 20 min at 4°C at 
16 000 xg. The supernatant was transferred to a fresh tube and the protein concentration was 
determined by using the Bradford protein assay reagent.  
2.16.2. Bradford assay 
The Bradford protein assay is a colorimetric protein assay. At a low pH, the used dye 
Coomassie Blue G is present in a protonated form and has a red color. When protein binds, 
the dye donates the protons and the color shifts to blue with an absorbance maximum of 
595 nm. The increase of absorbance at 595 nm is then proportional to the amount of protein 
present in the sample. A standard curve was created with bovine serum albumin (BSA) 
concentrations ranging from 0.5 μg to 6 μg to calculate the protein concentration of the 
samples. Then, 200 μl Bradford protein assay reagent was added. The protein concentrations 
were determined by measuring the absorption at 595 nm using a microplate reader (Model 
680, Bio-Rad) and calculated via the Microplate Manager® program. 
2.16.3. SDS Page 
SDS-Polyacrylamide-electrophoreses enables to separate proteins in an electric field based on 
their size. A discontinuous system consisting of separation and stacking gel was used. The 
running buffer contains SDS (sodium dodecyl sulphate) breaks up the non-covalent bonds and 
thereby leads to denaturation of the protein. The anionic properties of SDS lead to a negative 
charge of the SDS-protein-complex. This way, the speed of migration is only dependent on 
the size of the protein. Additionally, reducing reagents like β-mercaptoethanol are used to 
break down disulfide bonds and thus disrupt the protein structure. In the stacking gel (pH 6.8), 
the proteins are brought to a consistent front. They migrate between the fast migrating 
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chloride-ions and the slower migrating glycine-ions. In the separation gel (pH=8.8), glycin 
ionizes and passes the protein samples. The proteins can therefore move depending on size. 
SDS-PAGE gels were used in concentrations of 10% and 12% for resolving gels and 5% for 
the stacking gel (according to Table 18). The resolving gel was prepared first and covered 
with isopropanol. After polymerization, the stacking gel poured on top of the resolving gel 
after having removed the isopropanol.  
Table 18: Composition of SDS PAGE gels 
 stacking gel (mL) resolving gel (mL) 
5% 10% 12% 
H2O 6.8 9.9 8.2 
30% acrylamide mix 1.7 8.3 10 
1.5 M Tris pH 8.8 - 6.3 6.3 
1 M Tris pH 6.8 1.25 - - 
10 % SDS 0.1 0.25 0.25 
10 % ammonium persulfate 0.1 0.25 0.25 
TEMED 0.01 0.01 0.01 
 
The protein sample (containing 80-100 µg protein) was supplemented with Laemmli loading 
buffer (100 mM Tris pH 6.8, 4% SDS, 0.2% bromophenol blue, 20% glycerol, 5% β-
mercaptoethanol), denaturized (5 min, 95°C) and loaded onto the SDS Page gel. The gels 
were run at a current of 40 mA. For protein size determination, the PageRuler
TM
 marker was 
used. 
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2.16.4.  Immunoblotting 
For detection of proteins by antibody staining, the separated proteins on the gel had to be 
transferred to a nitrocellulose membrane by Western blotting. The nitrocellulose membrane 
was equilibrated in transfer buffer (25 mM Tris, 192 mM glycine, 20% methanol). Membrane 
and blotting paper were well soaked with transfer buffer before arranging them as follows on 
the semidry blot chamber: 3 filter papers, membrane, gel, 3 filter papers.  
The blotting was performed in transfer buffer at 2 mA/cm
2
 for 60 min. The efficiency of the 
transfer was determined by Ponceau-S Staining. Subsequently, the membrane was blocked 
with 5% milk powder in PBS for 1 h at RT. Staining with the primary antibody was done by 
incubating the membrane in an antibody dilution overnight at 4°C. The membrane was 
washed three times for 15 min in PBS and in the following incubated with the secondary 
antibody for 1 h at RT. The primary antibody is detected by horseradish peroxidase (HRP) 
conjugated secondary antibodies that target the Fc portion of the primary antibody. After 
washing the membrane 3 times in PBS for 15 min, the membrane was incubated with self-
made ECL (100 mM Tris-HCl, pH 8.5, 2.65 mM H2O2, 0.45 mM luminol, and 0.625 mM 
coumaric acid) for 1 min or commercially available ECL for 5 min. Chemiluminescence 
detection was performed by using chemiluminescence sensitive films or the LAS3000 system. 
 
2.17.  Statistics  
All the statistical evaluations were performed using Graphpad Prism 4 software. Statistical 
analysis was performed using unpaired Student`s two-tailed t-test. Data are shown as means ± 
SEM. Values of p < 0.05 (*p < 0.05) were considered statistically significant. 
 




The role of PHD2 in macrophages has not been completely elucidated yet. In this project, two 
different models were used to investigate the effect of PHD2 deficiency in macrophages, i.e. 
BMDM and RAW cells. RAW cells are easy to cultivate and to genetically manipulate. 
BMDMs on the other hand are primary cells and thus resemble the in vivo situation better 
than the cell line. Thus, to gain insight into the functional consequences of an inhibition of 
PHD2, stably transduced RAW cells expressing constitutively a shRNA targeting PHD2 and 
BMDM isolated from wt or LysM Cre x PHD2
fl/fl
 mice were used. Primary BMDM isolated 
from LysM Cre x PHD2
fl/fl
 had been characterized in the literature before. However, 
metabolic alterations have not been analyzed in these cells. Since hypoxic adaptation is 
accompanied by changes in the cellular metabolism, the metabolic phenotype of PHD2 
deficient macrophages was determined. Furthermore, I also analyzed if these change would 
alter the functionality of PHD2 deficient macrophages and how this is linked to the metabolic 
alterations at the molecular level.  
 
3.1. PHD2 deficient macrophages stabilize HIF-1α and show a HIF 
target gene expression pattern in normoxia 
The experiments in this study were performed using BMDM isolated from PHD2
 
cKO mice 
and PHD2 knockdown RAW cells (shPHD2). The knockout and the knockdown of PHD2 
respectively were confirmed on protein level (Fig. 6). To this end, wt and shPHD2 RAW cells 
as well as BMDM wt and PHD2 cKO macrophages were cultivated in normoxic (20% O2) 
and hypoxic (1% O2) conditions for 24 h. Subsequently, cells were lysed and lysates were 
analyzed by Western blotting. PHD2 protein levels were significantly decreased in both 
PHD2 deficient macrophage cell models. The decrease in PHD2 protein levels could be 
observed under normoxic as well as hypoxic conditions. Whereas in the wt cells PHD2 
protein levels increased in hypoxia in line with the fact that PHD2 per se is a HIF target gene, 
no comparable effect was observed in the shPHD2 and cKO cells. As a consequence of an 
efficient knockdown of PHD2, HIF-1 protein levels are expected to increase since its 
degradation is inhibited. HIF-1α levels were indeed increased in the shPHD2 RAW cells and 
cKO cells compared to wt cells in normoxia. In contrast, in wt BMDMs and RAW cells HIF-
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1proteinlevels were detected at low levels in normoxia and levels increased significantly 
only in hypoxic conditions. Taken together these experiments demonstrate that the PHD2 
deficient RAW cell line model and the cKO BMDMs used in this project exhibit a 
biologically relevant reduction of PHD2 with subsequent stabilization of the HIF-1α protein.  
 
Figure 6: PHD2 protein levels are downregulated in shPHD2 cell and PHD2 cKO BMDMs. wt and shPHD2 RAW cells 
as well as BMDM wt and cKO macrophages were cultivated in normoxia (20% O2) or hypoxia (1% O2) for 24 h. 
Subsequently cells were lysed and lysates were analyzed for HIF-1α, PHD2 and β-actin protein levels by Western blotting. 
PHD2 is described to be the main regulator of HIF stability in normoxia. Upon stabilization 
of the HIF subunit and heterodimerization with the constitutively expressed HIF subunit, 
the transcription factor HIF-1 induces the expression of its target genes. Since the above 
described Western blot experiments indicated that HIF-1 was sufficiently stabilized in the 
PHD2 deficient shPHD2 and cKO BMDMs in normoxia, I next analyzed how this effect is 
translated into altered HIF target gene expression. Therefore, I examined the mRNA 
expression levels of HIF target genes (including PHD2) in PHD2 cKO BMDM and shPHD2 
cells in normoxia and hypoxia (Fig. 7). PHD2 cKO BMDM and shPHD2 RAW cells showed 
an 80% reduction of PHD2 mRNA compared to wt BMDM and wt RAW cells, which is in 
line with the observed decreased PHD2 protein levels. Among the known HIF target genes, 
especially metabolism-related target genes were selected for the RNA analyses namely 
GLUT-1, PFK1, PDK1, COX4-2, LonP and BNIP3. All of these target genes were 
upregulated in hypoxia in the wt cells indicating that the used experimental setup enables to 
demonstrate the cellular hypoxic response. In the shPHD2 RAW cells and PHD2 cKO 
BMDM, the mRNA expression of GLUT-1, PFK1, PDK1, COX4-2, LonP and BNIP3 mRNA 
was increased in normoxic conditions compared to the respective wt cells, which reflects the 
constitutive activation of the HIF system in these cells in normoxia. PHD3 mRNA expression 
is highly induced in hypoxia, which could also be seen in the wt cells in this study. 
Comparable to the metabolism-related HIF target genes PHD3 mRNA levels were 
significantly increased in the shPHD2 RAW and PHD2 cKO cells in normoxia compared to 
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the wt cells. Most interestingly, however, the levels did not match the strong hypoxic 
induction of PHD3 mRNA levels in the wt cells indicating that the hypoxic gene expression 
pattern in the PHD2 deficient cell models just partly mimicked the response of the wt cells in 
hypoxia.  
While HIF-1 protein levels are significantly affected at the posttranslational level in 
hypoxia, HIF-1 mRNA levels do not respond to hypoxia (Wenger et al., 1997). This was 
also the case in the cell models used in this study. mRNA levels of HIF-1α were not affected 
by PHD2 deficiency or exposure to hypoxia. Taken together, the gene expression pattern of 
the PHD2 cKO and shPHD2 RAW cells resembled the induction of HIF target genes in wt 
BMDMs and wt RAW cells after incubation in hypoxia with the exception of PHD3 which 
was much stronger induced under hypoxic conditions.  
 
Figure 7: PHD2 deficient RAW and BMDM macrophages show an induction of HIF target genes in normoxic 
conditions. RAW wt and shPHD2 knockdown and BMDM wt and PHD2 cKO macrophages were incubated for 24 h at 20% 
or 1% O2. Subsequently cells were lysed and mRNA was isolated. mRNA levels of HIF target genes and HIF-1 itself were 
analyzed by qRT-PCR. The mRNA levels of RAW wt and BMDM wt cells (in normoxia) were set to one. The mRNA levels 
of shPHD2 or the PHD2 cKO BMDM or wt cells in hypoxia of the indicated genes are displayed as fold change compared to 
the wt cells in normoxia. n = 3-6 samples per condition. mean ± SEM, * p<0.05 
The target gene expression in the PHD2 deficient macrophages observed in normoxia is most 
likely mediated via HIF-1. To test for this assumption, the mRNA levels of PHD2/HIF-1α 
cKO BMDMs and the respective wt control cells were analyzed in normoxia and hypoxia 
(Fig. 8). Similar to the PHD2 cKO BMDMs, the double deficient (PHD2/HIF-1α cKO) 
BMDMs demonstrated a strong reduction in PHD2 mRNA levels, which was accompanied by 
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a significant decrease of HIF-1 mRNA levels. In stark contrast to the above described effect 
seen in the PHD2 cKO BMDM, none of the analyzed HIF target genes was significantly 
increased in normoxic conditions. This demonstrates that indeed the hypoxic expression 
pattern of the HIF target genes seen in the PHD2 cKO BMDMs in normoxia is at least mainly 
mediated via HIF-1.  
 
Figure 8: PHD2/HIF-1α cKO BMDMs have unchanged or downregulated gene expression levels of HIF target genes 
in normoxic conditions. BMDM wt and PHD2/HIF-1α cKO macrophages were incubated for 24 h at 20% or 1% O2. The 
RNA expression levels of the indicated genes were analyzed by qRT-PCR. The RNA levels of BMDM wt cells were set to 
one. The RNA levels of PHD2/HIF-1α cKO BMDM or wt cells in hypoxia of the indicated genes are displayed as fold 
change compared to the wt cells in normoxia. n = 3 samples per condition. mean ± SEM, * p<0.05 
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3.2. Migration and phagocytosis capacity is altered in PHD cKO 
and shPHD2 cells. 
3.2.1. PHD2 deficient macrophages migrate less than wt macrophages 
Macrophages are motile cells and need to be able to migrate into the surrounding tissue. To 
obtain insight into the effects of PHD2 deficiency on macrophage physiology, the migratory 
capacity of PHD2 deficient macrophages was assessed using two different experimental set 
ups. Transmigration capacity was investigated using a Boyden chamber experimental setup. 
In addition to that, single cell migration capacity was assessed by determining the 
accumulated distance of migrated cells.  
In the Boyden chamber experimental set up, wt and shPHD2 RAW as well as wt BMDM and 
BMDM cKO macrophages were confronted with either FCS-containing medium or with the 
conditioned supernatant of MDA-MB 231 breast carcinoma cells (Fig. 9 A). Migration was 
increased in the RAW cells and BMDM after stimulation with MDA-MB 231-conditioned 
supernatant. PHD2 cKO and shPHD2 cells were however found to migrate less compared to 
their respective wt cells in the transwell migration assay. This effect was seen after 
stimulating the cells with FCS and was even more prominent after stimulation with the 
conditioned MDA-MB 231 supernatant. Whereas in Boyden chamber experiment a mixture of 
cell invasion and migration is analyzed, single cell migration experiments allow analyzing the 
migration capacity per se. Therefore, the accumulated distance in single cell experiments over 
a time course of 6 h was analyzed (Fig. 9 B). The cells were either stimulated with FCS or 
conditioned MDA-MB 231 supernatant. The accumulated migration distance of shPHD2 
RAW cells and cKO BMDM was significantly reduced compared to the wt cells after 
stimulation with FCS as well as after stimulation with conditioned MDA-MB 231 
supernatant.  




Figure 9: A reduction of PHD2 expression in RAW cells or BMDMs results in a defect in macrophage migration. (A) 
RAW wt, RAW shPHD2, BMDM wt and PHD2 cKO cells were tested for their migration capacity in Boyden chambers 
using fetal calf serum (FCS) or conditioned medium of MDA-MB 231 cells as a stimulus. n = 3 (RAW cells), n = 4 (BMDM) 
(B) The accumulated migration distance over 6 h of RAW wt, shPHD2 RAW, BMDM wt and PHD2 cKO cells was tested in 
single cell migration experiments using FCS or conditioned medium of MDA-MB 231 cells as stimulus. Bright field images 
were taken every 10 min over a period of 6 h. Migration was analyzed using the cell tracking software ImageJ, n = 59-64 
cells per condition (RAW cells), n = 51-71 cells per condition (BMDM cells). Graphs show one representative experiment of 
a set of 4-5 (Boyden chamber) and 3 (single cell migration) experiments. mean ± SEM, * p<0.05 
 
In addition to measuring the migration of PHD2 deficient RAW cells and BMDMs, the 
migratory behavior of PHD2 cKO peritoneal macrophages was investigated. BMDMs are 
isolated from the bone marrow and differentiated over a time course of 7 days in vitro. In 
contrast, peritoneal macrophages are fully differentiated at the time of isolation and therefore 
even closer resemble the in vivo situation. Single cell migration experiments were performed 
with peritoneal macrophages isolated from PHD2 cKO mice and wt siblings. Freshly isolated 
peritoneal macrophages were subsequently tested for their migration capacity after 
stimulation with FCS or MDA-MB 231 conditioned medium. Comparable to the results 
obtained with the RAW cells and the BMDM migration of PHD2 cKO peritoneal 
macrophages was reduced compared to wt macrophages in both FCS and MDA-MB 231-
conditioned medium (Fig. 10).  




Figure 10: Peritoneal macrophages isolated from PHD cKO mice results in a defect in cell migration. The accumulated 
migration distance over 6 h of wt and PHD2 cKO peritoneal macrophages was tested in single cell migration experiments 
using FCS or MDA-MB 231 cell-conditioned medium as a stimulus. Bright field images were taken every 10 min over a 
period of 6 hours. Migration was analyzed using the cell tracking software ImageJ, n = 45-69 cells per condition. Graphs 
show one representative experiment of a set of 3 experiments. mean ± SEM, * p<0.05 
Deficiency of PHD2 in RAW cells or BMDMs led to the stabilization of HIF-1α in normoxic 
conditions. A similar effect can be obtained by chemical inhibition of PHD activity in wt 
cells. PHD enzymes use α-ketoglutarate as substrate during the hydroxylation reaction. 
Competitive inhibition of the α-ketoglutarate binding results in inhibition of the enzymatic 
activity. DMOG is a potent α-ketoglutarate analogue and is proposed to act as a competitive 
inhibitor against α-ketoglutarate dependent dioxygenases, such as PHDs. Similar to the 
genetic deletion of PHD2, DMOG treatment results in HIF-1 stabilization in normoxia. 
Thus, inhibition also the two other PHD isoforms would also be inhibited with DMOG 
treatment. It was tested, if pharmacological inhibition of PHD activity with DMOG affects 
single cell migration capacity of RAW wt cells (Fig. 11). The accumulated distance was 
found to be significantly decreased after stimulating the cells either with FCS or MDA-MB 
231 conditioned cell culture medium. Besides α-ketoglutarate, oxygen is the natural 
endogenous substrate of the PHD-mediated hydroxylation reaction. Hence, a reduction of the 
available oxygen concentration should result in a comparable effect as the treatment with 
DMOG. To test this hypothesis wt RAW cells were exposed to normoxic (20% O2) or 
hypoxic (1% O2) conditions. Single cell migration was tested under both conditions. Similar 
to the DMOG treated cells, hypoxic conditions significantly reduced the accumulated distance 
of the RAW wt cells.  




Figure 11: Migration of RAW wt cells is affected by DMOG and hypoxia exposure. RAW wt cells were incubated at 
20% O2 ± 1 mM DMOG or 1% O2 for 6 h. The accumulated migration distance was tested in single cell migration 
experiments using FCS or conditioned medium of MDA-MB 231 cells as stimulants. For cells analyzed in hypoxia, the 
hypoxic conditions were maintained during the single cell migration experiments without reoxygenation. n = 50-53 cells per 
condition. Graph shows one representative experiment out of a set of 2-3 experiments mean ± SEM, * p<0.05 
Taken together, a reduction of PHD2 protein expression via a shRNA targeting PHD2 (RAW 
cells) or via a Cre LoxP system (BMDM) results in an impaired migration capacity of 
macrophages. Similar effects can be observed after chemical inhibition of PHD activity via 
treatment of wt macrophages with the α-ketoglutarate analogue DMOG or by exposing the 
cells to hypoxic conditions.  
3.2.2. Phagocytosis is impaired in shPHD2 RAW and PHD2 cKO macrophages 
After having reached the site of inflammation, macrophages phagocytose invading pathogens 
and cell debris. Therefore, phagocytosis is regarded as another good indicator for macrophage 
function besides migration. Phagocytosis can be determined by the uptake of fluorescently 
labeled beads. Fluorescence intensity of the cells reflects the uptake of the particles in these 
experiments. Similar to the experimental design described above, phagocytosis capacity was 
tested in the wt RAW, shPHD2, wt BMDM, and cKO cells (Fig. 12). Cells were either 
exposed to normoxic (20% O2) conditions, hypoxic (1% O2) conditions or treated with 
DMOG. Phagocytosis capacity was found to be significantly reduced in the shPHD2 and cKO 
cells compared to the wt cells. Exposing the wt macrophages to hypoxia or treatment with 
DMOG mimicked this effect observed in PHD2 deficient macrophages in the wt cells. 




Figure 12: PHD2 deficient macrophages show a defect in phagocytosis. RAW wt, ShPHD2 RAW, BMDM wt and PHD2 
cKO cells were incubated at 20% O2 ± 1 mM DMOG or 1% O2 in total for 20 h. Then, fluorescently labeled beads were 
administered to the cells for another 4 h without reoxygenation. The capacity of the cells to phagocytose labeled beads was 
then analyzed. n = 5 samples per condition. Graphs show one representative experiment of a set of 3 experiments. mean ± 
SEM, * p<0.05. 
3.2.1. Cell proliferation is not affected by PHD2-deficiency in RAW cells 
In principle resident macrophages are capable of self-renewal by local proliferation. In 
contrast, activated macrophages in contrast most commonly die during their course of action. 
Cell proliferation is an energy-consuming process and relies on the provision of sufficient 
ATP similar to migration and phagocytosis. Cell proliferation of RAW wt and shPHD2 
macrophages was determined over 7 days (Fig. 13). To this end cells were seeded with a 
defined cell number and cell numbers were counted every day. Based on the cell counts, the 
doubling time was determined. Even though the cell numbers were slightly decreased in 
shPHD2 RAW cells at day 3 and 5 of the assay, in general there was not a significant 
difference between wt and shPHD2 cells. This is also reflected by the fact that the doubling 
time of the two cell lines is not significantly different.  




Figure 13: Cell proliferation is unchanged in wt and shPHD2 RAW macrophages. Cells were seeded at a concentration 
of 2x104 cells per dish and counted at the consecutive days for 7 days. Cell number is given as the logarithm of the cell 
number. Additionally, the doubling time (DT) was calculated based on the cell counts. n = 3 per condition. Graphs show one 
representative experiment out of a set of 2 experiments. mean ± SEM, * p<0.05. 
 
3.3. PHD2 deficient macrophages have an altered metabolism 
3.3.1. ATP levels are reduced in PHD2 cKO and shPHD2 macrophages 
To maintain proper cell function, cells rely on a fully functional cellular metabolism to 
produce sufficient ATP and meet energy demands. Activated macrophages utilize mainly 
glycolytic ATP to maintain integrity. As several HIF target genes that were found to be 
upregulated in the PHD2 deficient macrophages (chapter 3.1), play a role in the regulation of 
energy metabolism, the effect of PHD2 deficiency on cellular ATP levels was investigated 
(Fig. 14). The source for ATP production might change in normoxic (20% O2) compared to 
hypoxic (1% O2) conditions. Therefore, ATP levels were investigated in cells cultured at both 
oxygen concentrations. Levels of ATP were significantly diminished in the PHD2 cKO 
BMDM and shPHD2 RAW cells in normoxia (Fig. 14 A). In wt cells, ATP levels were 
reduced in hypoxia to similar levels as observed in the cKO BMDM and shPHD2 RAW cells 
in normoxia. Interestingly, in the PHD2 deficient cells ATP levels were even further reduced 
after exposure to hypoxia. Inhibition of PHD activity via treatment with DMOG mimicked the 
effect seen in the shPHD2 and cKO cells in normoxia as well as the effect seen in wt cells in 
hypoxia (Fig. 14 A). 




Figure 14: ATP levels are reduced in PHD2 deficient macrophages. (A) RAW wt, shPHD2 RAW, BMDM wt and PHD2 
cKO cells were incubated at 20% O2 or 1% O2 for 24 h. Intracellular ATP levels were determined. n = 6 samples per 
condition. (B) RAW wt cells were incubated for 6 and 24 h with 1 mM DMOG. Subsequently intracellular ATP levels were 
determined. Graphs show one representative experiment of 5 (A) or 4 (B) sets of experiments. n = 6-7 per condition. mean ± 
SEM, * p<0.05. 
3.3.2. Oxygen consumption rate is altered in PHD2 cKO and shPHD2 cells 
The adaptation to hypoxic conditions involves a metabolism shift from aerobic to anaerobic 
glycolysis. This can be explained in part by the fact that mitochondrial respiration consumes 
oxygen which needs to be saved when oxygen availability is scarce. To gain insight into the 
metabolic profile of the wt and PHD2 deficient cells the oxygen consumption rate (OCR) was 
analyzed. The OCR was measured while interfering with mitochondrial respiration by 
addition of chemicals using a Seahorse XF96 analyzer (Fig. 15 A and B). 
The basal OCR of the PHD2 cKO and the shPHD2 cells was significantly decreased 
compared to the respective wt. Adding Oligomycin to the cells blocks their ATP synthase. 
Therefore, oligomycin can be used to distinguish between the amount of oxygen consumption 
of the cells due to proton leak and the amount of oxygen consumption due to ATP synthesis. 
Addition of oligomycin indeed decreased the OCR. The effect of oligomycin was more severe 
in the wt compared to PHD2 deficient cells. This further supported the fact that mitochondrial 
ATP synthesis is reduced in PHD2 cKO and shPHD2 macrophages. Addition of FCCP allows 
analyzing the maximal respiration of the cells. The maximal respiration after uncoupling the 
mitochondria with the ionosphere FCCP was also significantly decreased in the PHD2 
deficient cells compared to the respective wt cells. This shows that the capacity of the 
shPHD2 and PHD2 cKO macrophages to use the mitochondria for respiration is reduced, thus 
the maximal respiratory capacity is decreased. Inhibition of complex I and III by the inhibitors 
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rotenone and Antimycin A blocks mitochondrial respiration. This then shows the residual 
OCR, which is not due to mitochondrial respiration. In the PHD2 cKO as well as the shPHD2 
cells, this residual respiration was still decreased compared to the respective wt cells. This 
indicates that not only mitochondrial OCR, but also other oxygen-consuming pathways are 
affected by PHD2 deficiency.  
Taken together, basal and maximal respiration are significantly affected as a consequence of 
decreased PHD2 levels in RAW cells and BMDMs. This finding strongly indicates that 
aerobic glycolysis is reduced in these cells due to the switch to anaerobic glycolysis. 
 
Figure 15: Oxygen consumption rate is decreased in PHD2 deficient macrophages. (A) RAW wt, shPHD2 RAW, 
BMDM wt and PHD2 cKO cells were tested for their oxygen consumption rate (OCR) after addition of XF-medium, 
oligomycin, FCCP as well as rotenone and antimycin A (Rot +AA). n = 6 (RAW) and n = 10 (BMDM) samples per 
condition. (B) Basal respiration and maximum respiratory capacity were analyzed in RAW wt, shPHD2 RAW, BMDM wt 
and PHD2 cKO cells based on the experiment shown in A. The OCR after Rot +AA addition was subtracted from the OCR 
after XF addition (basal respiration) and after FCCP uncoupling (maximal respiration). Graphs show one representative 
experiment of a set of 4-6 experiments. mean ± SEM, * p<0.05 
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OCR was also determined in RAW wt cells, which were treated with DMOG (Fig. 16). 
Mitochondrial oxygen consumption was significantly reduced in the treated cells. This was 
observed for the basal respiration, the respiration after oligomycin addition and the maximal 
respiratory capacity after uncoupling the mitochondria with FCCP. Taken together, this 
indicates that PHD2 deficient macrophages heavily reduce mitochondrial oxygen 
consumption and that this can be mimicked by pharmacological inhibition of the PHDs.  
 
 
Figure 16: RAW wt cells treated with DMOG have depressed oxygen consumption rate. RAW wt cells treated with 
1 mM DMOG for 24 h were tested for their oxygen consumption rate (OCR) after addition of XF-medium, oligomycin, 
FCCP as well as rotenone and antimycin A (Rot +AA). n = 6 samples per condition. Basal respiration and maximum 
respiration were analyzed. The OCR after Rot +AA addition was subtracted from the other rates. Graphs show one 
representative experiment of a set of 3 experiments. mean ± SEM, * p<0.05 
3.3.3. Extracellular acidification rate is increased in PHD2 cKO and shPHD2 cells 
Anaerobic glycolysis for energy generation results in significantly higher rate of proton 
production compared to cells generating energy from oxidative phosphorylation. Therefore, 
the extracellular acidification rate (ECAR) indicates the energy source of the cell. To proof 
that as a consequence of a reduction of PHD2 macrophages switch to anaerobic glycolysis, 
the ECAR of wt, shPHD2 and cKO BMDM cells was analyzed (Fig. 17). In these 
experiments the ECAR was analyzed after the addition of glucose, which allows determining 
the glycolysis rate, and oligomycin, which indicates the glycolytic capacity.  
PHD2 cKO as well as shPHD2 cells displayed an increased ECAR compared to their 
respective wt cells after the inhibition of mitochondrial oxidative phosphorylation by 
oligomycin. The shPHD2 RAW cells showed not only an increased glycolytic capacity but 
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also the basal glycolysis measured after the addition of glucose was elevated. This effect was 
not observed in the shPHD2 cells.  
 
Figure 17: Extracellular acidification rate is increased in PHD2 deficient cells. (A) Extracellular acidification rate 
(ECAR) was determined in RAW wt, shPHD2 RAW, BMDM wt and PHD2 cKO cells or RAW wt cells treated with 1 mM 
DMOG for 6 h after addition of glucose, oligomycin and 2-deoxy glucose (2-DG). n = 6 samples per condition. (B) 
Glycolysis and anaerobic glycolytic capacity were analyzed based on the experiments shown in A. The ECAR measured after 
2-DG addition was subtracted from the ECAR after glucose (glycolysis) and oligomycin addition (glycolytic capacity). 
Graphs show one representative experiment out of a set of 3-4 experiments. mean ± SEM, * p<0.05 
3.3.4. Lactate levels are increased in PHD2 deficient macrophages 
In anaerobic glycolysis, glucose is converted to lactate. An increase in glycolysis therefore 
should be accompanied by an increase in lactate levels in the supernatant of the cells. The 
above described OCR and ECAR assays indicate that the shPHD2 and cKO macrophages 
mostly use anaerobic glycolysis for energy production despite an abundant presence of 
oxygen. To support these findings, lactate levels were determined in the supernatants of wt, 
shPHD2 and cKO macrophages cultured in normoxic (20% O2) or hypoxic (1% O2) 
conditions (Fig. 18). In line with the reduced OCR and increased ECAR, lactate levels in the 
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supernatants of PHD2 cKO and shPHD2 RAW cells were increased compared to their 
respective wt cells. Lactate levels were also increased after exposure of the cells to hypoxic 
conditions for 24 h, which indicates that the experimental conditions used are adequate to 
determine the well-described switch to anaerobic glycolysis in hypoxia. Treatment of wt 
RAW cells with DMOG mimicked the increased lactate levels in hypoxia although in 
absolute terms the levels were lower and were more comparable to the levels found in the 
shPHD2 cells. 
 
Figure 18: Lactate levels are increased in the supernatant of PHD2 cKO and shPHD2 RAW cells. Lactate levels were 
determined in the supernatant of RAW wt, shPHD2 RAW, BMDM wt and PHD2 cKO cells after incubation of the cells at 
the indicated conditions. n = 4 samples per condition. Graphs show one representative experiment of a set of 4-6 experiments. 
mean ± SEM, * p<0.05. 
3.3.5. Mitochondrial content of PHD2 deficient macrophages is unaltered 
A decrease in oxygen consumption accompanied by the increased ECAR and lactate levels as 
observed in the PHD2 deficient macrophages can result from various reasons. One possibility 
is as discussed in the previous chapter 3.3, a glycolytic switch in order save the available 
oxygen. Another possibility is that PHD2 deficiency affects the number of mitochondria per 
cell. To exclude that the observed phenotype is due to an altered mitochondrial number rather 
than a shift in cellular metabolism, the mitochondrial content was determined in the wt, 
shPHD2 and cKO macrophages. To this end the amount of the mitochondrial gene 
mitochondrial COX2 (mtCO2) was compared to the amount of the genomic DNA for the 
ribosomal subunit 18S (Fig 19) by qPCR. This ratio indicates indirectly the number of 
mitochondria per cell. No difference in the mtCO2/18S was observed in the shPHD2 or wt 
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RAW cells or in the PHD2 cKO and their respective wt. This indicates that the number of 
mitochondria is unaltered in the PHD2 deficient macrophages. 
 
Figure 19: Mitochondrial content is unaltered in shPHD2 and cKO macrophages compared to the respective wt cells. 
Mitochondrial content of wt and shPHD2 cells was analyzed by determining the ratio of the copy number for the 
mitochondrial gene mtCO2 and genomic DNA 18S. Graph shows one representative experiment out of a set of 2-3 
experiments n=6 samples per condition. mean ± SEM, * p<0.05 
3.3.6. Inhibition of mitochondrial respiration decreased migration 
To summarize the findings described so far, PHD2 deficient macrophages display a 
significantly impaired migration and phagocytosis, which are associated with a decrease in 
ATP production and mitochondrial oxygen consumption. To allow the conclusion that 
decreased mitochondrial oxygen consumption indeed results in an altered migration, RAW wt 
cells were treated with the mitochondrial complex I inhibitor rotenone. Subsequently, single 
cell migration was analyzed using the treated versus non-treated cells by stimulating the cells 
with FCS or MDA-MB 231 conditioned medium (Fig. 20). The importance of mitochondrial 
function for migration capacity was further stressed by the fact that single cell migration of 
RAW wt cells was found to be decreased when treated with rotenone.  




Figure 20: Rotenone treatment decreases migration of RAW wt cells in single cell migration experiments. The 
accumulated migration distance of RAW wt cells over 6 h after incubation of the cells ± 1 µM rotenone or DMSO (used as 
diluent control) for 24 h was determined in single cell migration experiments using FCS or MDA-MB 231 conditioned 
medium as stimulus. n = 51-53 cells per condition. Graph shows one representative experiment out of a set of 3 experiments. 
mean ± SEM, * p<0.05 
3.3.7. Mitochondrial ROS production is decreased in shPHD2 RAW cells 
In hypoxia, cells display a cytochrome c subunit switch. The cytochrome c subunit switch 
from COX4-1 to COX4-2 increases the efficiency of complex IV of the mitochondrial 
electron transport chain regarding the quantity of ATP and ROS produced (Fukuda et al., 
2007). Furthermore, the HIF-mediated increase of the glycolytic flux reduces the flux through 
the TCA cycle and the mitochondrial electron transport chain. This way, the accumulation of 
mitochondria-derived ROS is reduced. As described in chapter 3.1, the analysis of the mRNA 
levels in the shPHD2 cells indicated a cytochrome subunit switch. Additionally, analysis of 
the OCR and ECAR indicated a glycolytic switch. To investigate if these changes are 
associated with changes in mitochondrial ROS levels, ROS production was analyzed using 
mitochondria isolated from wt and shPHD2 RAW cells (Fig. 21). ROS accumulation was 
analyzed by DCF staining. Using this method, ROS accumulation was found to be 
significantly reduced as a consequence of the PHD2 knockdown in isolated RAW 
mitochondria. 




Figure 21: PHD2 affects mitochondrial ROS production. Mitochondria of wt and shPHD2 RAW cells were isolated and 
analyzed for ROS production by DCF staining. Graph shows one representative experiment of a set of 5 experiments mean ± 
SEM, * p<0.05 
3.3.8. Overall ROS production is increased in shPHD2 RAW cells 
Even though mitochondria are thought to be the main producers of cellular ROS, there are 
also many other mechanisms contributing to overall cellular ROS (reviewed in (Holmstrom 
and Finkel, 2014)). Total cellular ROS levels were analyzed by quantification of the 
EOH/DHE and the ethidium/DHE ratios in RAW wt and shPHD2 cells (Fig. 22). EOH/DHE 
indicates the amount of ROS due to superoxide (O2
•-
) production and the ethidium/DHE ratio 
indicates the amount of ROS due to H2O2 production and other ROS sources. Interestingly, 
while mitochondrial ROS production was reduced, the ROS production in complete cells was 
found to be increased. Both, i.e. the ratio for EOH indicating O2
•-
 and for Ethidium indicating 
H2O2, were found to be significantly increased in shPHD2 cells compared to wt cells. This 
shows that despite the decreased mitochondrial ROS production other ROS-producing 
pathways are increased in shPHD2 RAW cells. This results in a net increased ROS level in 
these cells. 
 




Figure 22: HPLC analysis of DHE derived products in whole cell lysates of wt and shPHD2 RAW cells. Quantification 
of EOH/DHE and ethidium/DHE ratios from RAW whole cell lysates. Cells were maintained in PBS and incubated with 
100µM DHE for 30 min and analyzed by HPLC. Graph shows one representative experiment of a set of 3 experiments. n = 3 
per condition. mean ± SEM, * p<0.05 
 
3.4. The metabolic alterations observed in PHD2 deficient 
macrophages depend on PDK1 
3.4.1. PDK1 protein levels are increased in PHD2 deficient macrophages 
PDK1 is an important factor mediating the switch from aerobic to anaerobic glycolysis (see 
chapter 1.3.4). PDK1 phosphorylates and thereby inhibits PDH which results in less pyruvate 
to be converted into acetyl-CoA. Pyruvate then is metabolized via the glycolytic pathway into 
lactate. As described in chapter 3.1, PHD2 cKO and shPHD2 cells had increased PDK1 RNA 
levels in normoxia, which was mediated via HIF-1To confirm this finding at the protein 
level, cell lysates of wt RAW, shPHD2, wt BMDM and cKO BMDM were prepared after 
culturing the cells for 24 h in normoxic (20% O2) or hypoxic (1% O2) conditions. Lysates 
were subsequently analyzed for PDK1 protein levels by Western blot analysis (Fig. 23). In all 
cells, PDK1 protein levels were significantly increased in hypoxia compared to normoxia. 
This is in line with the fact that PDK1 is a well characterized HIF target gene. In the PHD2 
deficient RAW cells and cKO BMDM, however, elevated PDK1 levels were also detected in 
normoxia compared to the wt control cells. These protein levels were comparable to the levels 
found in hypoxia. Accordingly, PDH was found to be more phosphorylated in the PHD2 cKO 
and shPHD2 RAW cells compared to their respective wt cells in normoxia whereas the 
  Results 
65 
 
amount of total PDH remained unchanged. As a loading control, -actin protein levels were 
analyzed.  
 
Figure 23: PDK1 protein levels are increased in PHD2 cKO and shPHD2 cells. Phospho-PDH, total PDH, PDK1 and β-
actin protein levels of RAW wt and shPHD2 cells as well as BMDM wt and PHD2 cKO macrophages in normoxia (20% O2) 
or hypoxia (1% O2 for 24 h). 
3.4.2. PHD2 deficient macrophages show a decreased activity of PDH 
PDK1 is the key enzyme for the glycolytic switch from aerobic to anaerobic metabolism. At 
the molecular level, this is reflected by enhanced phosphorylation of PDH. This 
posttranslational modification alters the activity of the pyruvate metabolizing enzyme. With 
increased phosphorylation the activity ceases, which prevents pyruvate to be fed into the TCA 
cycle. Since an increased phosphorylation of PDH was found in the shPHD2 and cKO 
macrophages, the activity of the enzyme was analyzed (Fig. 24). The activity of PDH was 
determined in cell extracts isolated from wt cells and shPHD2 RAW cells after exposure to 
normoxia (20% O2) or hypoxia (1% O2) for 24 h. Additionally, wt cells were treated with 
DMOG, lysed and subsequently tested for PDH activity. PDH activity was significantly 
reduced in shPHD2 cells in normoxia compared to wt cells. The wt cells showed a reduced 
activity of PDH after DMOG treatment or after exposure to hypoxia. However, PDH activity 
in the shPHD2 cells was still significantly lower in hypoxia compared to wt cells. The PDH 
activity thus reflected the phosphorylation pattern seen in the Western blots as well as the 
PDK1 mRNA and protein levels. 
 




Figure 24: PDH activity is decreased in shPHD2 cells. PDH activity in RAW wt, shPHD2 RAW cells and RAW wt cells 
treated with 1 mM DMOG for 24 h in normoxia or hypoxia (1% O2 for 24 h). n = 4-6 samples per condition. Graph shows 
one representative experiment of a set of 5 experiments. mean ± SEM, * p<0.05 
 
3.5. PDK inhibition by dichloroacetate (DCA)  partly restores the 
metabolic alterations in PHD2 deficient macrophages 
3.5.1. PDH activity in shPHD2 cells is restored by dichloroacetate treatment 
From the data of the previous chapters, a downregulation of PHD2 was associated with an 
induction of HIF target genes, an impaired migration and phagocytosis as well as an altered 
metabolism. An important regulator of the metabolic shift to glycolysis, PDK1 was found to 
be increased. In line with this, PDH activity was found to be reduced in PHD2 deficient 
macrophages. In order to obtain further insight into the role of PDK1 in the observed 
phenotype, the cells were treated with the PDK inhibitor dichloroacetate (DCA). Binding of 
DCA to PDK1 triggers conformational changes resulting in the inactivation of kinase activity 
(Kato et al., 2007). To test if inhibition of PDK1 by DCA treatment indeed reestablished the 
PDH activity in the shPHD2 RAW cells, wt and shPHD2 RAW cells were treated for 24 h 
with 5 mM DCA (Fig. 25). Subsequently, cells were lysed and analyzed for PDH activity. As 
demonstrated before in chapter 3.4.2, shPHD2 macrophages exhibited a significantly lower 
PDH activity compared to wt cells. In the DCA-treated shPHD2 cells however, an increase in 
PDH activity that partly resembles the activity observed in the wt, was detected. DCA did not 
have a significant effect on the wt cells.  




Figure 25: PDH activity is increased after treatment with dichloroacetate (DCA). PDH activity was determined in RAW 
wt and shPHD2 RAW cells after incubation of the cells ± 5 mM DCA for 24 h. n = 6 samples per condition. Graph shows 
one representative experiment of a set of 4 experiments. mean ± SEM, * p<0.05 
3.5.2. Lactate levels are decreased by DCA treatment 
The increase in PDH activity described above should result in a decrease in lactate levels as 
PDH converts pyruvate to acetyl CoA which should result in a decrease of anaerobic 
glycolysis and hence a reduction in the lactate levels produced. In line with the increased 
PDH activity, DCA treatment of PHD2 cKO and shPHD2 macrophages also affected lactate 
levels in these cells (Fig.26). The increase in lactate levels found in the untreated shPHD2 and 
PHD2 cKO macrophages could be decreased by treating them with 5 mM DCA for 24 h. 
Even though PDH activity was not found to be affected by DCA treatment in the wt cells, 
lactate levels were also reduced in the DCA treated wt. This could indicate that DCA also has 
a minor effect on PDH activity in the wt RAW cells which cannot be detected by this assay, 
but in an assay where an endpoint is measured, such as the accumulation of lactate. However, 
the effect on lactate levels seems to be stronger in the shPHD2 and PHD2 cKO macrophages. 
 




Figure 26: Lactate levels are decreased upon DCA treatment. Lactate levels in the supernatants of RAW wt, shPHD2 
RAW, BMDM wt or PHD2 cKO macrophages after incubation of the cells ± 5 mM DCA for 24 h, n=4-5 samples per 
condition. Graphs show one representative experiment of a set of 3-5 experiments. mean ± SEM, * p<0.05 
3.5.3. DCA reduces glycolysis in PHD2 deficient macrophages 
DCA treatment was observed to reverse the effect of PHD2 deficiency on PDH activity and 
lactate levels. To further confirm that 5 mM DCA treatment for 24 h is sufficient to reverse 
the glycolytic phenotype of the PHD2 cKO and shPHD2 cells, also the changes in glycolysis 
in wt and PHD2 deficient cells treated with DCA were measured. In accordance with the 
increased PDH activity and the reduced lactate levels, glycolysis observed in PHD2 deficient 
macrophages was also decreased after DCA treatment when analyzing the ECAR (Fig. 27 A, 
B). Treatment with DCA reduced the increased acidification rate found in PHD2 cKO and 
shPHD2 cells. This was observed for both the basal glycolysis and the glycolytic capacity of 
the cells (Fig. 27 B). DCA treatment also reduced glycolysis and glycolytic capacity in wt 
cells which is consistent with the observation that also lactate levels are affected by DCA in 
the wt cells. 
 




Figure 27: Extracellular acidification rate is reduced by DCA treatment. (A) Extracellular acidification rate (ECAR) was 
determined in RAW wt, ShPHD2 RAW, BMDM wt and PHD2 cKO cells after addition of glucose, oligomycin and 2-deoxy 
glucose (2-DG) after an incubation time of 24 h with ± 5 mM DCA. n = 6-10 samples per condition. (B) Glycolysis and 
anaerobic glycolytic capacity were analyzed based on the ECAR after addition of glucose (glycolysis) and oligomycin 
(glycolytic capacity). The ECAR after 2-DG addition was subtracted from the other rates. Graphs show one representative 
experiment of a set of 3-4 experiments. mean ± SEM, * p<0.05  
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3.6. DCA partially restores macrophage function in PHD2 deficient 
macrophages. 
3.6.1. Single cell migration in shPHD2 cells can be restored by DCA treatment 
As described in the previous chapters, treatment of the metabolic phenotype of PHD2 
deficient macrophages could be at least partly reversed with DCA treatment. Treatment with 
DCA for 24 h partly re-established wt metabolism and reduced anaerobic glycolysis in these 
cells. The metabolism of macrophages is closely connected to cellular function. Therefore, it 
was tested if macrophage function could also be normalized by PDK-inhibition in PHD2 
deficient macrophages. For that reason, I analyzed the migratory behaviour of shPHD2 cells 
that were treated with DCA in a single cell migration assay in response to FCS-containing 
medium and MDA-MB 231 supernatant over a time course of 6 h (Fig. 28). DCA treatment of 
shPHD2 RAW cells normalized the migratory behavior in a single cell migration 
experimental setup and increased it up to wt levels whereas migration in the wt was 
unaffected by DCA treatment. This effect was even more prominent in the MDA-MB 231-
stimulated conditions.  
 
Figure 28: DCA treatment increases migration in a single cell migration experiment. The accumulated migration 
distance over 6 h of RAW wt and ShPHD2 RAW cells after incubation of the cells ± 5 mM DCA for 24 h was determined in 
single cell migration experiments using FCS or MDA-MB 231 conditioned medium as stimulus. n = 20-68 cells per 
condition. Graph shows one representative experiment out of a set of 3 experiments. mean ± SEM, * p<0.05 
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3.6.2. Migration in a Boyden chamber assay is not affected by DCA treatment 
In addition to the single cell migration assay I investigated the effect of DCA treatment of 
PHD2 deficient macrophages in a Boyden chamber assay (Fig.29). The Boyden chamber 
assay allows to analyze a mixture of cell migration, but also of cell invasion. Therefore, I 
analyzed if the effect of DCA could be recapitulated in this transwell migration assay. In 
contrast to the re-established migration observed in response to DCA treatment in the single 
cell migration experiment, no such effect could be observed in the Boyden chamber assay. 
Migration of the DCA-treated RAW wt and shPHD2 was not rescued by DCA treatment. 
macrophages in the Boyden chamber assay. Also DCA treated BMDM wt and PHD2 cKO 
macrophages did not display an altered transwell migration compared to their untreated 
controls. This indicates that even though the ability of PHD2 deficient macrophages to 
migrate in a plane, such as a cell culture dish is enhanced by DCA-treatment, it does not affect 
the transmigration capacity of the cells.  
 
Figure 29: DCA treatment does not affect migration in a Boyden chamber experiment. RAW wt, shPHD2 RAW, 
BMDM wt and PHD2 cKO cells treated ± 5mM DCA for 24 h were tested for their migration capacity in Boyden chambers 
using fetal calf serum (FCS) or conditioned medium of MDA-MB 231 cells as stimulus. n = 6 (RAW cells), n = 4 (BMDM). 
mean ± SEM, * p<0.05. 
3.6.3. DCA treatment increases phagocytosis in PHD2 deficient macrophages 
Besides migration, phagocytosis is also a suitable indicator of macrophage function. I 
therefore analyzed if phagocytosis could be influenced by pharmacological inhibition of PDK. 
Phagocytosis was measured by the uptake of fluorescent beads after 24 h of DCA treatment. 
shPHD2 and PHD2 cKO and the respective wt cells were either treated with 5 mM DCA for 
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20 h or left untreated, then fluorescent beads were added for additional 4 h for the cells to 
phagocytose (Fig. 30). The phagocytosis of the shPHD2 RAW and PHD2 cKO macrophages 
was increased upon DCA treatment and was almost normalized to wt levels. The capacity of 
wt RAW and wt BMDMs to perform phagocytosis was not altered by DCA treatment.  
Taken together, the data obtained from the effect of DCA treatment in the phagocytosis assay 
and from the observations made in the single cell migration experiment upon DCA treatment 
indicate that the metabolic programming via PDK1 is at least partly responsible for the 
functional impairment observed in PHD2 deficient macrophages.  
 
Figure 30: Phagocytosis is reestablished in DCA-treated PHD2 deficient macrophages RAW wt, shPHD2 RAW, 
BMDM wt and PHD2 cKO cells were incubated ± 5 mM DCA for 24 h. Subsequently, the capacity of the cells to 
phagocytose labeled beads was analyzed. n = 5-8 samples per condition. Graphs show one representative experiment of a set 
of  4-6 experiments. mean ± SEM, * p<0.05. 
 




Macrophages are important effector cells of the innate immune system and play a major role 
in the phagocytosis of invading pathogens and in the mediation of homeostatic processes 
(Goren et al., 2009; Mirza et al., 2009). In the past years, it was shown that macrophages have 
an important role in ischemic disease and that they accumulate inside the tissue after 
myocardial infarction (Azzawi et al., 2005). Ischemic tissues are characterised by regions of 
hypoxia and nutrient depletion. This triggers several stimuli leading to tissue cell activation 
and macrophage invasion into the tissue. Therefore, macrophages have to migrate against the 
oxygen gradient. To adapt to the scarce oxygen availability, macrophages and other cell types, 
express a specific gene expression program mediated by HIF. The stabilization of HIF is 
dependent on the oxygen sensitive regulation of the HIF-1α subunit by the three PHDs 
(Bruick and McKnight, 2001; Epstein et al., 2001). PHD2 is the main regulator of HIF-1α 
stability in normoxic conditions and deficiency of PHD2 is sufficient to stabilize HIF-1α and 
to induce HIF-1 mediated gene expression. Induction of this gene expression program results 
in the induction of angiogenesis, erythropoiesis, but it also leads to the expression of genes 
that are involved in metabolism, such as glucose transporters and genes involved in glycolysis 
(reviewed in (Goda and Kanai, 2012)). Previous studies revealed significant tissue and cell 
type specific effects of PHD2, but the role of PHD2 in macrophages has not been fully 
elucidated yet. This study describes an effect of PHD2 deficiency on macrophage metabolism 
and function.  
 
4.1. HIF-target genes are differentially expressed in PHD2 cKO and 
shPHD2 RAW macrophages 
In PHD2 deficient macrophage models, PHD2 was found to be decreased on RNA and 
protein level resulting in HIF-1α stabilization in normoxic conditions. Knockdown of PHD2 
or knockout resulted in the induction of HIF target genes in normoxic conditions. The mRNA 
levels of HIF target gene PHD3 is increased in shPHD2 RAW cells and PHD2 cKO 
macrophages in normoxic conditions. The compensatory increase of the PHD3 upon a 
knockdown of PHD2 was already described in other cell- and tissue-specific PHD2 knockout 
mouse and cell line models (Holscher et al., 2011; Marxsen et al., 2004). In hypoxia, HIF 
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strongly induces the expression of PHD3 and to a lesser extent PHD2 (Epstein et al., 2001; 
Metzen et al., 2005; Pescador et al., 2005). It has been proposed that this is to provide a 
negative feedback loop to limit the hypoxic response during prolonged hypoxia (del Peso et 
al., 2003; Minamishima et al., 2009) . HIF-1 mRNA levels are unaffected by PHD2 
deficiency. It has been previously reported that HIF-1α activity is regulated by protein 
stabilization rather than regulation of mRNA expression levels (Wenger et al., 1997). HIF-1α 
protein levels were even further increased in hypoxia in the shPHD2 RAW cells and PHD2 
cKO BMDMs showing that the 80% reduction in PHD2 levels was not efficient enough to 
induce maximal HIF-1α stabilization in normoxia. This is further supported by the fact that 
HIF target gene expression was further increased in the shPHD2 and PHD2 cKO cells 
compared to normoxia. RAW wt cells and wt BMDMs induce the expression of HIF target 
genes in hypoxia which is in line with the literature (Cramer et al., 2003). HIF-1 triggers a 
differential gene expression which in turn regulates several cellular processes to ensure 
optimal adaptation of the cell to the limited oxygen availability. This is achieved by genes that 
affect the metabolism of the cell and switch the source for energy generation from aerobic to 
anaerobic glycolysis. For example, glucose uptake is increased by upregulation of GLUT1 
(Ebert et al., 1995; Hayashi et al., 2004). The glycolytic flux is augmented by the upregulation 
of PFK1 and PDK1 (Obach et al., 2004; Papandreou et al., 2006). PDK1 inhibits the activity 
of PDH which catalyzes the conversion of pyruvate to acetyl-CoA (Papandreou et al., 2006). 
Thus, less acetyl-CoA is provided to the TCA cycle and pyruvate is converted to lactate for 
energy generation. Another adaptation mechanism is the subunit isoform switch from COX4-
1 to COX4-2 in the mitochondrial complex IV of the respiratory chain (Fukuda et al., 2007). 
This exchange is mediated by LonP which degrades COX4-1. The switch from COX4-1 to 
COX4-2 results in an increased efficiency of complex IV regarding the amounts of ATP 
produced and decreases the mitochondrial oxygen consumption. HIF also triggers BNIP3 
expression to induce mitochondrial autophagy and to limit ROS levels (Bruick, 2000; Zhang 
et al., 2008). All these genes were found to be induced in shPHD2 RAW cells and PHD2 cKO 
cells. This indicates that the metabolism of these cells is changed. The induction of the genes 
in PHD2 deficient macrophages was HIF-1-dependent as the genes found to be upregulated in 
normoxia in the PHD2 cKO and shPHD2 cells were unchanged or decreased in HIF-1α/PHD2 
cKO BMDMs. This indicates that the HIF-1α stabilization due to PHD2 deficiency is an 
important factor in the gene expression pattern found in the shPHD2 RAW and PHD2 cKO 
macrophages.  
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4.2. Macrophage function is altered in PHD2 deficient macrophages 
 The main task of macrophages is to recognize and migrate towards foreign bodies, worn-out 
cells and other debris and to engulf them in order to remove them from the system. Hence, 
analysis of the migration capacity and the phagocytosis properties of macrophages provide a 
good indication on the general macrophage fitness. 
4.2.1. Migration and phagocytosis is impaired in PHD2 cKO and shPHD2 
macrophages  
The PHD2 deficient shPHD2 RAW and PHD2 cKO macrophages used in this project 
displayed impaired phagocytosis and migration. The migration of PHD2 deficient 
macrophages was significantly reduced in a single cell migration experiment and also in a 
transwell migration assay. The phagocytosis of fluorescently-labeled beads by both RAW 
cells and BMDMs was decreased in the PHD2 deficient cells. Thus, PHD2 deficiency results 
in a diminished macrophage function in RAW cells and BMDMs. This impairment in 
macrophage function was not associated with a reduced proliferation rate in shPHD2 cells 
indicating that the most basic cellular functions are not affected by PHD2 deficiency. The 
defect in migration of PHD2 deficient macrophages is in line with other reports (Ikeda et al., 
2013; Mamlouk et al., 2014). Mamlouk et al. showed that shPHD2 RAW cell and PHD2 
deficient peritoneal macrophage migration toward macrophage chemoattractant protein-1 
(MCP-1) as a stimulus was decreased. Additionally, Ikeda et al. reported that in LysM Cre 
PHD2
fl/fl
 animals, less macrophages infiltrated the aorta in a model of hypertensive 
cardiovascular remodeling (Ikeda et al., 2013). However, these studies did not provide further 
insight into the underlying mechanisms. One might argue that the migration and phagocytosis 
deficit depends on the stabilization of HIF-1α in PHD2 deficient macrophages. This 
hypothesis could be tested by analyzing migration and phagocytosis in HIF-1α KO 
macrophages or macrophages that overexpress HIF-1α. Several other groups investigated the 
role of HIF-1α in the context of macrophage function. HIF-1α knockout in myeloid cells was 
described to decrease migration of peritoneal macrophages in a Boyden chamber (Cramer et 
al., 2003; Semba et al., 2016). Phagocytosis was also impaired in macrophages lacking HIF-
1α (Peyssonnaux et al., 2005). On the other hand, phagocytosis was also impaired in RAW 
macrophages that overexpress HIF-1α as shown by the significantly lower intracellular counts 
of bacteria (Shirato et al., 2009). The opposite findings in PHD2 and HIF-1α-KO models 
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stress that the influence of PHD2 and HIF-1α stabilization on migration and phagocytic 
capacity is not easily answered and requires more investigation. In this context, it is important 
to mention that there are indications for PHD dependent alternative substrates (reviewed in 
(Wong et al., 2013)). PHD dependent alternative substrates might explain why a loss of PHD2 
function not always mimics a HIF-1α gain of function..  
4.2.2. Treatment with DMOG or exposure to hypoxia also reduces migration and 
phagocytosis of macrophages 
In the RAW wt macrophages, I found single cell migration to be reduced in the single cell 
migration experiment by exposure to hypoxia or by treatment with the PHD inhibitor DMOG. 
This resembled the migratory defects found in the shPHD2 RAW cells. The effect of hypoxia 
on migration is not well established in the literature. Some groups report an increase in 
migration, other groups find that migration is impaired under hypoxic conditions (Raheja et 
al., 2011; Semba et al., 2016; Turner et al., 1999; Vogler et al., 2013). Reasons for the 
divergence in the findings might be differences in the oxygen percentage defined as hypoxia 
in the studies, the exposure time to hypoxia and the experimental model used. In a 
macrophage model, it was recently reported that 4 h of hypoxia (1% O2) resulted in an 
increase of thioglycollate-stimulated peritoneal macrophages in a transwell migration assay 
(Semba et al., 2016). A study conducted with THP1 cells and human peritoneal macrophages 
found an impairment in migration under hypoxic conditions (Turner et al., 1999). My data 
indicate that the ability of macrophages to migrate suffers in hypoxia.  
Furthermore, the phagocytosis phenotype could be mimicked by exposing the cells to hypoxic 
conditions and by pharmacological inhibition of the PHDs with DMOG. In contrast to my 
findings, Anand et al. reported an increased phagocytosis in RAW cells in hypoxic conditions. 
However, one has to keep in mind the differences in the experimental set up. Whereas I 
exposed the cells to 24 h of hypoxia or DMOG, in the report by Anand et. al. the longest 
exposure time was 8 h. It might well be that the exposure time to hypoxia and thus the time of 
HIF-stabilization contributes to these opposite findings. It might be that when encountering a 
region of hypoxia, macrophages first heavily migrate towards the site of hypoxia and start to 
phagocytose cellular debris, but if the hypoxia is not resolved, the capacity of the 
macrophages to phagocytose might cease. One possible explanation for this could be that the 
energy pool of the macrophages might be exhausted by the long term dependence on 
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anaerobic glycolysis. This hypothesis is further supported by the fact that long term 
stabilization of HIF-α by PHD2 deficiency also reduces phagocytosis in my model and that 
the ATP levels decrease in hypoxia and PHD2 deficient macrophages.  
 
4.3. PHD2 deficiency in macrophages results in metabolic 
reprogramming 
Otto Warburg first described that tumor cells in contrast to normal cells, use “fermentation” of 
glucose to lactate additionally to oxidative phosphorylation and independent from the oxygen 
availability (Warburg et al., 1927). Thus, tumor cells would use anaerobic glycolysis even in 
conditions with sufficient oxygen. Anaerobic glycolysis is characterized by a reduction in 
OCR and an increase in lactate levels. The PHD/HIF-1 pathway was described earlier to 
mediate a metabolic change that will shift the cellular metabolism form aerobic to anaerobic 
glycolysis. Therefore, it was analyzed if PHD2 deficiency affects the metabolic profile of the 
cells.  
4.3.1. Macrophage energy metabolism is altered by PHD2 deficiency 
ShPHD2 RAW cells and PHD2 cKO macrophages had decreased ATP levels compared to the 
respective wt control cells. Furthermore, ATP levels were even further reduced by hypoxia 
and by inhibition of PHDs by DMOG. The drop in ATP levels after exposure to hypoxia is in 
accordance with other studies conducted (Fukuda et al., 2007; Heerlein et al., 2005; Weinberg 
et al., 2000; Zhang et al., 2008). The ATP levels in the PHD2 deficient cells dropped even 
further in hypoxic conditions and the hypoxic reduction in ATP was more severe in the PHD2 
deficient macrophages compared to wt cells. This shows that the effect of PHD2 deficiency 
cannot be completely resembled by 24 h hypoxia and does not show the maximal effect. This 
might be explained by the fact that the knockdown efficiency of my model is not strong 
enough to mimic hypoxic conditions completely. Furthermore, a role of the other remaining 
PHDs in maintaining the ATP pool cannot be excluded. Especially PHD1 has been described 
to impact cellular metabolism (Aragones et al., 2008). 
In hypoxic conditions, cells switch their metabolism in favor of anaerobic glycolysis in order 
to cope with the scarce oxygen availability. In shPHD2 RAW and PHD2 cKO cells, OCR was 
found to be decreased and glycolysis was found to be increased. Consequently, lactate levels 
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were also elevated. This was also the case when using the PHD inhibitor DMOG. This shows 
that PHD2 deficient macrophages switch their metabolism to anaerobic glycolysis. An 
increase in lactate levels in macrophages in hypoxia was also reported by others (Meiser et al., 
2015; Semba et al., 2016). Recently it was shown that in the liver PHD2-deficiency induces a 
glycolytic gene expression profile and increases lactate levels in mouse embryonic fibroblasts 
(Suhara et al., 2016). This observation is in line with my findings. PHD2 deficient RAW cells 
and BMDMs display all features which indicate that the cells underwent metabolic 
reprogramming. This means that PHD2 deficient macrophages display a decreased oxygen 
consumption rate with increased glycolysis which is accompanied by reduced ATP levels. 
Taken together, my data indicates that PHD2-deficiency in macrophages is sufficient to 
trigger a glycolytic phenotype in normoxic conditions which is comparable to the Warburg 
effect. 
Changes in metabolism of macrophages were described to be associated with macrophage 
polarization. M1 polarized macrophages were shown to be more glycolytic and to induce an 
attenuation of the mitochondrial respiratory chain (reviewed in (Galvan-Pena and O'Neill, 
2014)). The accumulation of TCA cycle intermediates results in an increase in cellular ROS 
levels which is used for bacterial killing. Takeda et. al. showed in a heterozygous PHD2
+/- 
- 
mouse model that PHD2-deficiency in macrophages triggers M2 polarization (Takeda et al., 
2011). M2 polarized macrophages are described to use oxidative phosphorylation as the major 
ATP source (reviewed in (Galvan-Pena and O'Neill, 2014)). This is in contrast to my findings 
in the PHD2 cKO and shPHD2 RAW macrophages given that the glycolytic phenotype in my 
data would rather indicate a M1 polarization of PHD2 deficient macrophages. Data generated 
by Dr. Katja Farhat (unpublished, laboratory of Prof. Katschinki) revealed that macrophage 
polarization is unaltered in PHD2 cKO macrophages. This shows that the metabolic switch 
observed in PHD2 deficient macrophages is independent from a switch in polarization.  
It was reported previously that in response to hypoxia, HIF triggers the induction of BNIP3 
which in turn induces mitochondrial autophagy to prevent increased ROS levels (Bellot et al., 
2009; Zhang et al., 2008). In PHD2 deficient macrophages, I found an induction of BNIP3 
mRNA, but the mitochondrial number of these macrophages remained unchanged indicating 
that mitochondrial autophagy is not increased in these cells. Mitochondrial function has an 
important role in migration as inhibition of the mitochondrial complex I by rotenone reduced 
migration of RAW wt macrophages severely in a single cell migration experiment. 
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Mitochondria are the major source of cellular ATP generation, thus it is not surprising that an 
energy consuming process such as cell migration, is affected by decreased mitochondrial 
function. In line with the present study, a role of mitochondria was reported earlier for the 
migratory capacity of MDA-MB 231 cells (Zhao et al., 2013). When treated with 
mitochondrial inhibitors CCCP and oligomycin, cellular migration was reduced. Thus, 
interfering with the mitochondrial respiratory chain inhibits the migratory capacity of the 
cells. In the shPHD2 and PHD2 cKO macrophages, mitochondrial respiration is 
downregulated. It might be that the reduced oxidative phosphorylation in these cells 
contributes to the impaired migration.  
4.3.2. ROS levels are differently altered in shPHD2 RAW isolated mitochondria and 
total cells. 
The amount of ROS production in hypoxia is still under debate whereas some studies report a 
decrease in mitochondrial ROS in response to hypoxia (Archer et al., 1989; Hoffman et al., 
2007; Paky et al., 1993), other groups report an increase in ROS levels (Bell et al., 2007; 
Chandel et al., 2000; Guzy et al., 2005). The increase of ROS is proposed to result from a 
hypoxia induced conformational change in complex III (ubiquinol cytochrome c 
oxidoreductase) of the respiratory chain (Guzy et al., 2005; Mansfield et al., 2005). This 
change is supposed to enhance the interaction between the ubisemiquinone radical and O2 
thereby increasing superoxide formation. One hypothesis for the increase of mitochondrial 
ROS production in hypoxic conditions is that the increased abundance of ROS results in the 
accumulation of iron in the Fe
3+
- state (reviewed in (Taylor, 2008)). Fe
3+
 cannot be used as a 
cofactor by the PHDs, thereby attenuates PHD activity and thus hypoxic ROS would increase 
HIF-α stabilization. Indeed, adding ROS such as hydrogen peroxide was sufficient to trigger 
HIF-α stabilization in normoxic conditions (Bell et al., 2007). One hypothesis for the decrease 
of ROS in hypoxic conditions proposed that the inhibition of mitochondria in hypoxia results 
in a reduction in oxygen consumption which results into less oxygen used by the 
mitochondria (reviewed in (Taylor, 2008)). This reduction in mitochondrial oxygen utilization 
will increase the availability of oxygen in the cytosol and can be used by the PHDs to limit 
the hypoxic response. In my PHD2 deficient models, I found mitochondrial ROS production 
to be reduced. The role of PHD2 in mitochondrial ROS production has not been described 
earlier. Mitochondrial ROS production, at least in isolated mitochondria was not increased in 
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the model used here. Regarding the hypothesis that mitochondria reduce ROS in order to 
repress HIF signaling, this would mean that long-term HIF-α stabilization, as induced by 
PHD2 deficiency, triggers a mechanism that reduces mitochondrial ROS. This might happen 
in order to reduce HIF signaling by PHDs. The reduction in mitochondrial ROS production 
seems to be independent from the actual oxygen availability within the cell as the experiment 
was performed at normoxic conditions. It was shown by others that isolated rat mitochondria 
reduce their ROS production with decreasing oxygen concentration (Hoffman et al., 2007). 
Assuming that the mitochondrial ROS production is dependent on HIF-1α stabilization, this is 
line with the finding that mitochondria isolated from PHD2 deficient macrophages display 
reduced ROS levels.  
Interestingly, in contrast to the reduced mitochondrial ROS production, I found an increase in 
total cellular ROS levels. This is surprising given that the mitochondria are widely assumed to 
be a major source of cellular ROS. In quantitative manners, it was described at least for the 
liver that the endoplasmatic reticulum and peroxisomes have a greater capacity to produce the 
ROS H2O2 (Boveris et al., 1972). For other cell types, it is evident that the mitochondria are 
an important ROS source, but the actual contribution of mitochondrial ROS to the net cellular 
ROS is missing (reviewed in (Brown and Borutaite, 2012)). The ROS elevation observed in 
the total cells might also be due to the increased activity of ROS-producing enzymes, such as 
nitric oxidases, lipoxygenases and NADPH oxidases (Nox) (reviewed in (Holmstrom and 
Finkel, 2014)). Especially, the Nox enzymes were described to have a function in hypoxic 
conditions. Nox4 levels were found to be increased in cardiomyocytes and in pulmonary 
vasculature in hypoxic conditions (Mittal et al., 2007; Wang et al., 2014). This upregulation 
had a significant role in the promotion of microvascular angiogenesis after 
hypoxia/reperfusion injury. Also Nox2 mediated ROS production was shown to have a role in 
the ischemic response in the mobilization and expansion of progenitor cells in the bone 
marrow (Urao et al., 2012). These mechanisms might also contribute to an increased ROS 
production.  
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4.4. The metabolic alterations observed in PHD2 deficient 
macrophages depend at least partially on PDK1 
PDK1 is a key regulator in glucose metabolism mediating the switch from aerobic to 
anaerobic respiration. This ensures metabolic homeostasis and saves oxygen in hypoxic 
conditions. PDK1
-/-
 mice with a cardiomyocyte specific knockout of PDK1 die of heart failure 
between 5 and 11 weeks of age (Mora et al., 2003). Cardiomyocytes isolated from these mice 
were notably more sensitive to hypoxia compared to wt cardiomyocytes stressing the 
importance of PDK1 in the adaptation to hypoxia.  
PDK1 levels and the amount of phosphorylated PDH are increased in shPHD2 RAW cells and 
PHD2 cKO BMDMs on protein levels. This correlated with a decreased PDH activity in 
shPHD2 RAW cells in normoxic conditions. The phenotype of the shPHD2 cells could be 
mimicked by treating the wt cells with DMOG or by exposing the cells to hypoxia. The 
reduction of PDH flux in resting macrophages in hypoxic conditions had been reported earlier 
and is in line with my findings (Meiser et al., 2015). The PDH activity in the shPHD2 cells is 
still reduced compared to wt cells in the hypoxic conditions indicating that PDH activity is 
not completely blocked in the wt cells in hypoxia. This is in line with the finding that lactate 
levels are still increased and ATP levels are reduced in the shPHD2 cells compared to wt after 
24 h of hypoxia. One possible explanation for this phenotype might be that the effect of 
hypoxia is more severe in cells that already have an increased HIF-1α stabilization due to 
PHD2 deficiency. In a wt situation, HIF-1 induces PHD2 and PHD3 during hypoxia thereby 
limiting the hypoxic response. This pathway will be hampered in the PHD2 deficient cells 
resulting in an augmented hypoxic response. This is furthermore supported by the fact that the 
induction of HIF-target genes in hypoxic conditions was generally increased in the shPHD2 
and PHD2 cKO macrophages compared to wt cells. 
To obtain further insight into the role of PDK1 in the metabolic shift observed in PHD2 
deficient macrophages, I treated the cells with the PDK-inhibitor dichloroacetate (DCA). To 
date, there are four known PDK isoforms in mammals, i.e. PDK1-4. PDKs inactivate the PDH 
complex by phosphorylating it at three serine residues (Ser232, Ser293 and Ser300) (Rardin et 
al., 2009). PDK1 is the only one of the PDKs which phosphorylates all three sites (Kolobova 
et al., 2001). Mutagenesis studies on recombinant human PDH revealed that phosphorylation 
on any of the three serine residues is sufficient to inhibit the dehydrogenase activity in vitro 
(Korotchkina and Patel, 1995). PDKs are activated by high abundances of acetyl Co-A, 
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NADH and ATP and are inhibited by high amounts of ADP and pyruvate (Kerbey et al., 
1976). The pyruvate mimetic DCA is just 150 Da in size and therefore easily crosses the 
cellular membrane (Michelakis et al., 2008). Binding of DCA to PDK1 triggers 
conformational changes in the nucleotide- and lipoyl-binding pockets of PDK1 (Kato et al., 
2007). This results in inactivation of the kinase activity. DCA is the most commonly used 
inhibitor of PDK enzymes. In the literature, it is used in a wide range from 0.5 mM to 100 
mM (reviewed in (Kim et al., 2006)), mostly to induce a cytotoxic effect on cancer cells 
which depend heavily on energy generation by lactate production. Bonnet et. al. showed that 
DCA induces apoptosis in cancer cells, but not in normal cells stressing the dependence of 
cancer cells on glycolysis (Bonnet et al., 2007). Inactivation of PDKs results in a shift of 
cellular metabolism by forcing more energy to be generated by feeding acetyl-CoA into the 
respiratory chain. DCA is also described to have implications in inhibiting mitochondrial 
hyperpolarization by reactivations of a mitochondrial potassium-ion channel axis and inhibit 
tumor growth (Bonnet et al., 2007).  
In the RAW cell line model, DCA had no significant effects on the PDH activity of wt 
macrophages. In the shPHD2 cells on the other hand, it significantly increased PDH activity. 
Thus, the repression of PDH activity observed in the shPHD2 RAW cells can be reestablished 
by inhibiting PDK by DCA. The increased activity of PDH should result in an increase in 
oxidative phosphorylation and a decrease in lactate levels, thereby reverting the metabolic 
shift of the PHD2 deficient macrophages 
  
4.5. Inhibition of PDK1 by DCA partially reestablishes wt 
phenotype in PHD2 deficient macrophages 
PHD2 deficient shPHD2 RAW cells and PHD2 cKO cells displayed a reduction in ATP 
levels, a depressed oxygen consumption rate and an increase in glycolysis. This metabolic 
phenotype was at least partly reversible by inhibition of PDK1. Inhibiting PDK1 with DCA 
was sufficient to decrease lactate levels and glycolysis and to restore the migratory capacity in 
a single cell migration experiment and phagocytosis. This indicates that PDK1 is the 
important factor mediating the metabolic changes and functional alterations in PHD2 deficient 
macrophages. Previous studies revealed an important role of PDK1 in macrophages (Tan et 
al., 2015). Even though, no effect of PDK1 induction on macrophage polarization could be 
observed in this model, the described regulation of glucose metabolism is in line with my 
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findings. In the model used in the presented thesis, inhibition of PDK1 by DCA resulted in 
increased PDH activity in shPHD2 RAW cells that partly resembled the PDH activity of wt 
cells. Furthermore, DCA treatment also resulted in a reduction in glycolysis and in lactate 
levels. Functionally, it increased the phagocytosis of shPHD2 and PHD2 cKO macrophages. 
In addition to that, also single cell migration was reestablished in the shPHD2 cells. 
Interestingly, inhibition of PDK1 by DCA was not sufficient to reestablish migration in PHD2 
deficient macrophages in a Boyden chamber experimental set up. This indicates that the 
mechanisms involved in transwell migration are not affected by the metabolic switch, but 
rather via different mechanisms. One possible explanation could be that PHD2 deficient 
macrophages display an alternate set of chemokine receptors that is expressed independently 
from the metabolic changes. Chemokines are a family of small proteins that serve as stimulus 
for leukocyte migration. These chemokines bind to the chemokine receptors and thereby 
trigger cell migration. Hypoxia was described earlier to influence the expression of 
chemokine receptors (Bosco et al., 2006; Schioppa et al., 2003). For example, it was reported 
in human monocytes that the expression of CXC chemokine receptor (CXCR) 4 is 
upregulated in hypoxic conditions (Schioppa et al., 2003). Furthermore, a transcriptome 
screen of primary human macrophages revealed that the chemokine receptors CCR5, CCR1 
and CCR2 are downregulated in hypoxia (Bosco et al., 2006). The shPHD2 cells have an 
increased expression of HIF-1α in normoxia. Thus, chemokine receptors might be differently 
regulated in the shPHD2 cells. The expression of chemokine receptors would not be affected 
by the inhibition of PDK1 and hence, no effect on transmigration by DCA treatment could be 
observed.  
Transmigration of macrophages is a very delicate process that involves cytoskeletal 
rearrangements and the activation of several pathways resulting in the polarization of the 
macrophage (reviewed in (Imhof and Aurrand-Lions, 2004)). Effective migration requires the 
formation of lamellipodia in the anterior region of the cell as well as the formation of uropod 
at the end of the macrophage. Thus, it might be possible that PHD2 deficiency affects 
macrophage transmigration capacity by a different arrangement of the cytoskeleton. The 
cytoskeletal rearrangements involve the rearrangements of actin microfilaments (F-actin) 
which control cell mobility. Actin polarization is regulated by numerous proteins, the best 
studied are the small GTPases of the RhoA family, their regulators and their effector proteins 
(reviewed in (Ridley, 2015)). The small GTPases cycle between a GDP bound (inactive) and 
a GTP-bound (active) state. The best characterized small GTPases are RhoA, Rac1 and 
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Cdc42. They are needed for the organization of the actin cytoskeleton (RhoA), lamellipodia 
(Rac1) and filopodia (Cdc42). Cytoskeletal rearrangements in hypoxia mediated by i.e. the 
RhoA GTPase pathway have been described for several cell types and might provide a 
possible explanation for the observed phenotype (Choi et al., 2015; Raheja et al., 2011; 
Vogler et al., 2013). Inhibition of PDK1 by DCA results in partially reestablished wt 
metabolism of the PHD2 deficient macrophage, but as these metabolic changes do not affect 
the cytoskeleton of the cells, it might explain why macrophage transmigration is not rescued 
by metabolism reestablishment.  
 
4.6. PHD2 might provide an useful tool to influence macrophage 
metabolism and function 
The PHD2 deficient macrophage models used in this project exhibited impairment in 
migration and phagocytosis. This indicates that PHD2 has a role in the mediation of 
macrophage function. In inflammation, the response of these macrophages is likely to be 
altered compared to wt macrophages. It remains to be investigated if PHD2 positively or 
negatively regulates macrophage function in inflammation. PHD2 deficient macrophages 
might migrate slower to the site of inflammation and once there, these macrophages will 
contribute less to the clearance of the affected tissue as they are less capable to phagocytose. 
Macrophages are crucial for the tissue remodeling after myocardial infarction, but they can 
also be detrimental to the healing process (reviewed in (Liu et al., 2016)). Macrophages 
accumulate in the infarcted area and are involved in phagocytosis, angiogenesis, inflammation 
and collagen deposition. Several groups reported an effect of PHD2 deficiency in 
macrophages in different disease models (Ikeda et al., 2013; Mamlouk et al., 2014; Takeda et 
al., 2011). For example in a cancer model, it was shown that myeloid specific PHD2 knockout 
mice exhibited a reduced tumor volume (Mamlouk et al., 2014). This finding was explained 
by the overall downregulation of cytokines which included pro-inflammatory as well as anti-
inflammatory cytokines. In a model of pharmacologically induced hypertension, PHD2 
deficiency in macrophages attenuated infiltration of macrophages and induced less 
inflammation and fibrosis which preserved heart function in a myeloid specific PHD2 KO 
(Ikeda et al., 2013). Additionally, it was also described that PHD2
+/- 
mice were protected from 
myocardial ischemia and exhibited an increased viability of ischemic tissue in a model of 
hindlimb ischemia. This was reported to be associated with a M2 polarization of the PHD2 
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deficient macrophages (Takeda et al., 2011). These reports would argue for a beneficial effect 
of PHD2 deficiency in macrophages. On the other hand, macrophages were also described to 
be essential to proper tissue repair after myocardial infarction (MI) (Nahrendorf et al., 2011). 
The removal of dead cells and debris by macrophage phagocytosis is important for the 
resolution of the inflammation. Therefore, less macrophages at the site of inflammation which 
at the same time have a reduced rate of phagocytosis might also result in a worse outcome. 
The defect in macrophage function described in this project initiated another project 
investigating the effect of PHD2 cKO macrophages in a model of MI. Unpublished data 
generated by Angelika Beneke (laboratory of Prof. Katschinski) demonstrate that in the PHD2 
cKO mice, the migration kinetics of the PHD2 deficient macrophages into the infarcted heart 
is shifted. This might indicate a delayed migration of the PHD2 deficient macrophages into 
the tissue and would be in line with my data. Furthermore, Angelika Beneke also found a 
significantly decreased heart function at day 7 after myocardial infarction which indicates that 
inhibition of PHD2 in macrophages might be disadvantageous in the context of MI. Thus, the 
effect of PHD2 deficiency on macrophages in disease is not easily answered and requires 
more investigation.  
PHD2 deficiency was sufficient to induce an anaerobic glycolytic metabolism in macrophages 
in normoxic conditions. The metabolism of macrophages was recently described to be 
connected to the effector function of the macrophages (Mills and O'Neill, 2016). In the case 
of PHD2 deficiency, the glycolytic phenotype is associated with a decreased abundance of 
ATP and with a defect in macrophage function. Thus, it might be possible that the function of 
macrophages can be regulated by metabolic changes due to PHD2 deficiency.  
The impairment in migration and phagocytosis could be mimicked by exposing the cells to 
hypoxia or by treating them with the PHD inhibitor DMOG. DMOG is a competitive α-
ketoglutarate analogue. Inhibiting the PHD/HIF pathway using α-ketoglutarate mimetics is a 
promising strategy for the development of new drugs. In fact, several PHD inhibitors (PHI) 
entered clinical trials for the treatment of different diseases. Roxadustat/FG-4592 recently 
entered stage III clinical trials for chronic kidney disease patients in order to treat renal 
anemia, but also other PHI are currently tested (reviewed in (Macdougall, 2012; Maxwell and 
Eckardt, 2015)). Until now, one of the used PHI, the PHI FG-226 was stopped to be tested 
because one of the patients developed severe hepatitis (reviewed in (Maxwell and Eckardt, 
2015)). The results of the phase III trials should be obtained within the next three years and 
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will give more information about possible applicability and adverse effects of PHIs. In 
addition to clinical trials, there is also plenty of preclinical evidence that the induction of the 
HIF pathway by PHI may be beneficial in tissue protection, for example during myocardial 
ischemia (reviewed in (Bishop and Ratcliffe, 2015) and (Vogler et al., 2015)). 
The metabolic reprogramming induced by PHD2 was reversible by inhibition of PDK1. This 
shows that the changes in metabolism are indeed crucial for the observed impairment in 
macrophage function. PDK1 was earlier described to be involved in macrophage function 
(Kawano et al., 2012). Myeloid specific PDK1
-/-
 KO mice on a high fat diet showed an 
increased accumulation of M1 polarized macrophages inside fat tissue. Furthermore, PDK1 
was found to be involved in the migration of macrophages. The observations by Kawano et. 
al. further stress the importance of PDK1 in macrophage migration as PDK1 deficient 
macrophages migrated significantly more compared to controls. In my model, PHD2 
deficiency is associated with increased PDK1 levels and decreased migration. The correlation 
between the level of PDK1 and migratory capacity is in line with my findings, even though 
transwell migration was not affected by PDK1 inhibition in my model. 
The anaerobic glycolytic phenotype was found to be reversible by DCA treatment. DCA 
treatment was also found to reestablish phagocytosis and single cell migration in the PHD2 
deficient macrophages which would implicate that DCA might be a useful tool in modulating 
macrophage function. The most extensively studied PDK inhibitor is DCA and it is used to 
reduce congenital lactic acidosis in children with mitochondrial disorders (Stacpoole, 1989; 
Stacpoole et al., 2006). Additionally, DCA is discussed as a treatment option for cancer 
therapy (reviewed in (Michelakis et al., 2008)). The Warburg effect which is characterised by 
the utilization of anaerobic glycolysis in the presence of oxygen depends on the shunting of 
acetyl-CoA away from the mitochondria. This process is mediated by PDK1. Inhibiting PDK1 
in cancer cells therefore reverses the Warburg effect and results in reduced proliferation and 
increased apoptosis of tumor cells. However, DCA was also shown to induce neurotoxicity in 
adults in a small blinded placebo controlled study that was conducted in patients with 
MELAS syndrome (Kaufmann et al., 2006). MELAS syndrome is defined by mitochondrial 
myopathy, encephalopathy, lactic acidosis and stroke-like episodes. In this study, it was 
observed that almost all the patients treated with DCA developed peripheral neuropathy. Thus 
inhibition of PDK1 using DCA would reestablish macrophage function, but due to its toxicity 
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the use is limited. PHD inhibitors, however, are currently tested in late stage clinical trials and 
until now seem to be relatively safe (reviewed in (Maxwell and Eckardt, 2015).  
Taken together, my data indicates that cellular metabolism and cell function can also be 
influenced by PHD2 in macrophages. PHD inhibitors have reached late stage clinical trials 
and seem to be relatively safe. The most commonly used PDK inhibitor DCA on the other 
hand was found to have severe adverse side effects in adults. Therefore targeting PHD2 might 
provide a better way to influence cellular metabolism and macrophage function than does 
targeting PDK directly.  
 




In the presented thesis the effect of PHD2 on metabolism and function of macrophages was 
described (Fig. 31). For this, primary BMDMs which harbor a homozygous knockout of 
PHD2 and a RAW cell line that stably express shRNA against PHD2 were used. Both models 
showed a decrease in PHD2 expression of approximately 80 %. PHD2 deficient macrophages 
showed a stabilization of HIF-1α and increased HIF target gene expression. The induction of 
the HIF target gene PDK1 led to a metabolic reprogramming which was associated with 
increased lactate levels and glycolysis, depressed OCR and a decrease in migration and 
phagocytic capacity. The decrease in oxygen consumption was not due to a reduced number 
of mitochondria. Furthermore, I found mitochondrial ROS production to be reduced and total 
cellular ROS to be increased. The underlying mechanisms to these seemingly contradictory 
findings remain to be investigated. However, my data clearly show that PHD2 deficiency 
negatively regulated PDH activity.  
A reduction in migration and phagocytosis, a decrease in ATP levels and an increase in lactate 
levels was more prominent in hypoxic conditions than in PHD2 deficient cells in normoxia. 
This suggests that the PHD2 knockdown efficiency was either not strong enough to induce the 
maximal effect or that additional mechanisms contribute to metabolic adaptation in hypoxia. 
The changes in metabolism in PHD2 deficient macrophages were dependent on PDK1 
activity. Inhibiting PDK1 with DCA was sufficient to decrease lactate levels and glycolysis 
and to restore the migratory capacity in single cell migration experiments and to restore 
phagocytosis. Transwell migration is supposedly mediated via a different mechanism because 
it was not affected by PDK inhibition. The underlying mechanism of this difference could not 
be answered within the work scope of this project and remains to be elucidated. 
In conclusion, my data indicate that PHD2 plays an important role in macrophage metabolism 
and function. PHD2 influences the balance between aerobic and anaerobic glycolysis via the 
expression of PDK1. Therefore, targeting PHD2 might provide a useful approach to influence 
the immune function of macrophages via metabolic reprogramming.  




Figure 31: PHD2 deficient macrophage undergo metabolic reprogramming dependent on PDK1. (A) PHD2 deficiency 
results in HIF-1α stabilization and HIF target gene expression, such as PDK1. PDK1 inhibits PDH which leads to a reduction 
of mitochondrial respiration which depends on acetyl-CoA as a substrate. Overall, this results in a reduction of cellular ATP 
and mitochondrial oxygen consumption. The mitochondrial ROS is reduced whereas total cellular ROS levels are increased. 
The inhibition of PDH by PDK1 results in an increased quantity of pyruvate utilized for energy generation by anaerobic 
glycolysis and thus lactate levels increase. Furthermore, PHD2 deficient macrophages have reduced migration and impaired 
phagocytosis. (B) Inhibiting PDK1 by DCA treatment reinstalled PDH activity and reduced glycolysis and thus normalized 
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